U.S. patent application number 12/757253 was filed with the patent office on 2010-10-28 for omp85 proteins of neisseria gonorrhoeae and neisseria meningitidis, compositions containing same and methods of use thereof.
This patent application is currently assigned to THE UNIVERSITY OF MONTANA. Invention is credited to RALPH C. JUDD, D. SCOTT MANNING.
Application Number | 20100272744 12/757253 |
Document ID | / |
Family ID | 22646935 |
Filed Date | 2010-10-28 |
United States Patent
Application |
20100272744 |
Kind Code |
A1 |
JUDD; RALPH C. ; et
al. |
October 28, 2010 |
OMP85 Proteins of Neisseria Gonorrhoeae and Neisseria Meningitidis,
Compositions Containing Same and Methods of Use Thereof
Abstract
Nucleic acid and amino acid sequences of the Omp85 proteins of
N. gonorrhoeae and N. meningitidis, and fragments thereof are
useful in vaccine compositions, therapeutic compositions and
diagnostic compositions for use in the prevention, treatment and
diagnosis of non-symptomatic gonococcal infection or symptomatic
disease and non-symptomatic meningococcal infection and symptomatic
disease. Antibodies are developed to these proteins and also useful
in the compositions and methods described herein.
Inventors: |
JUDD; RALPH C.; (FLORENCE,
MT) ; MANNING; D. SCOTT; (MISSOULA, MT) |
Correspondence
Address: |
HOWSON & HOWSON LLP
501 OFFICE CENTER DRIVE, SUITE 210
FORT WASHINGTON
PA
19034
US
|
Assignee: |
THE UNIVERSITY OF MONTANA
MISSOULA
MT
|
Family ID: |
22646935 |
Appl. No.: |
12/757253 |
Filed: |
April 9, 2010 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10606618 |
Jun 26, 2003 |
7794733 |
|
|
12757253 |
|
|
|
|
09994192 |
Nov 26, 2001 |
6610306 |
|
|
10606618 |
|
|
|
|
09177039 |
Oct 22, 1998 |
|
|
|
09994192 |
|
|
|
|
Current U.S.
Class: |
424/190.1 |
Current CPC
Class: |
A61P 31/04 20180101;
Y10S 530/825 20130101; G01N 33/56911 20130101; C07K 2319/00
20130101; G01N 2333/22 20130101; A61K 39/00 20130101; A61K 2039/53
20130101; C07K 14/22 20130101 |
Class at
Publication: |
424/190.1 |
International
Class: |
A61K 39/02 20060101
A61K039/02; A61P 31/04 20060101 A61P031/04 |
Goverment Interests
[0002] This invention was made with government support under grant
Nos. AI21235 and AI37777, awarded by the National Institutes of
Health. The government has certain rights in this invention.
Claims
1. A method of producing an immunogenic composition comprising
isolating a recombinant polypeptide comprising an epitope of at
least 8 consecutive amino acids within the amino acid sequence of
SEQ ID NO: 4, and providing said polypeptide with a
pharmaceutically acceptable carrier, wherein said composition
induces antibodies in a mammal that bind to said epitope of SEQ ID
NO: 4 and that interfere with adherence of Neisseria gonorrhoeae as
measured by the gonococcal cell adherence assay.
2. The method of claim 1, wherein said composition comprises a
second polypeptide or protein.
3. The method according to claim 2, wherein said second polypeptide
or protein is an antigen from a pathogenic bacterial species that
is heterologous or homologous to Neisseria gonorrhoeae or Neisseria
meningitidis.
4. The method according to claim 1, wherein said composition
further comprises an adjuvant.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. patent
application Ser. No. 10/606,618, filed Jun. 26, 2003, now pending,
which is a continuation of U.S. patent application Ser. No.
09/994,192, filed Nov. 26, 2001, now U.S. Pat. No. 6,610,306,
issued Aug. 26, 2003, which is a continuation of U.S. patent
application Ser. No. 09/177,039, filed Oct. 22, 1998, now
abandoned. All priority applications cited herein are expressly
incorporated by reference.
BACKGROUND OF THE INVENTION
[0003] This invention relates generally to the cloning and
identification of novel outer membrane proteins of several strains
of Neisseria, and more specifically to proteins useful in the
prevention, therapy and/or diagnosis of infection and diseases in
mammals caused by these strains.
[0004] The pathogenic Neisseriae cause several important
non-symptomatic infections and symptomatic diseases in humans.
Neisseria gonorrhoeae is the agent of non-symptomatic gonococcal
infection or symptomatic disease, i.e., gonorrhea. Neisseria
meningitidis is the agent of a rapidly progressive spinal
meningitis, which may also have a non-symptomatic infective stage.
The surfaces of such pathogens provide crucial interfaces for
interactions between the pathogen and the host. Many bacterial
virulence factors are outer membrane proteins, and surface exposed
proteins are the primary targets recognized and attacked by the
host's immune system. Thus, the role of outer membrane proteins is
of particular importance in understanding the pathogenesis of these
organisms. The most abundant and immunodominant outer membrane
proteins of the pathogenic Neisseriae have been studied extensively
(Sparling P. F. et al, Clin. Invest., 89: 1699-1705 (1992)). For
example, it is known that the immunodominant components of the
gonococcal surface are antigenically variant, suggesting that this
organism is capable of adapting to varying host environments while
avoiding host immune responses. Although the major gonococcal
surface proteins have been extensively studied, little is known
about less abundant proteins and their contributions to
pathogenesis.
[0005] Two-dimensional electrophoresis (IEF and SDS-PAGE) of
labeled, e.g., radioiodinated or biotinylated, gonococcal surface
proteins suggested that numerous (>20) of the less abundant
gonococcal outer membrane proteins remained uncharacterized
(unpublished observations). Among these might be proteins which
play an important role in infection.
[0006] For example, surface-exposed outer membrane proteins of
other microorganisms, e.g., Haemophilus influenzae D15 surface
antigen (D-15-Ag) and the Pasteurella multocida Oma87, have been
found to be useful in eliciting antibodies that were protective
against infectious challenge in animal models. The Omp85-like
D-15-Ag was conserved in both non-typeable and typeable strains of
H. influenzae and was recognized by convalescent patient sera;
affinity-purified anti-D-15-Ag serum was protective in the rat pup
model (Thomas, W. R., et al, Infect. Immun., 58:1909-1913 (1990);
Flack, F. S. et al, Gene, 156:97-99 (1995)]). H. influenzae
serotypes a-f, nontypeable H. influenzae and Haemophilus
parainfluenzae all expressed proteins similar to the D-15-Ag, as
demonstrated by immunoblot analysis. Antibodies to recombinant
D-15-Ag protected against H. influenzae type b and type a
bacteremia in the infant rat model (Loosmore, S. M. et al, Infect.
Immun., 65:3701-3707 (1997)).
[0007] Like H. influenzae D-15-Ag, the Oma87 of P. multocida was
highly conserved among strains and was recognized by protective
antibody; it was present in all 16 serotypes of P. multocida and
was recognized by convalescent animal sera. Antibodies raised to
recombinant Oma87 were protective against homologous challenge in
the mouse model (Ruffolo, C. G. et al., Infect. Immun.,
64:3161-3167 (1996)). Despite the several publications describing
the immunological properties of D-15-Ag and Oma87, the function of
these proteins remains unknown.
[0008] There remains a need in the art for the development of
proteins from Neisseriae which are useful in research, diagnosis
and treatment of the infections, especially non-symptomatic
infections, and the diseases caused by these pathogens.
SUMMARY OF THE INVENTION
[0009] In one aspect, the invention provides an isolated outer
membrane protein of N. gonorrhoeae having an apparent molecular
weight of 85 kDa and characterized by an amino acid sequence of SEQ
ID NO: 2, a fragment, an analog or a homolog thereof. In another
aspect, the invention provides a nucleic acid sequence encoding the
Omp85 of N. gonorrhoeae or a fragment thereof.
[0010] In still another aspect, the invention provides a nucleic
acid molecule comprising a nucleic acid sequence encoding the Omp85
of N. gonorrhoeae or a fragment thereof under the control of
suitable regulatory sequences which direct expression of said Omp85
protein or fragment in a selected host cell.
[0011] In yet a further aspect, the invention provides a host cell
transformed with the above described nucleic acid molecule.
[0012] In still a further aspect, the invention provides a method
of recombinantly expressing the Omp85 of N. gonorrhoeae or a
fragment thereof comprising the steps of culturing a recombinant
host cell transformed with a nucleic acid sequence encoding said
protein or fragment under conditions which permit expression of
said protein or peptide.
[0013] In another aspect, the invention provides a method for
preparing an Omp85 protein of N. gonorrhoeae or fragment thereof
comprising chemically synthesizing said protein or fragment.
[0014] In yet another aspect, the invention provides a diagnostic
reagent comprising a nucleic acid sequence encoding Omp85 of N.
gonorrhoeae, isolated from cellular materials with which it is
naturally associated, a sequence complementary thereto, a fragment
thereof, a sequence which hybridizes thereto under stringent
conditions, an allelic variant thereof, a mutant thereof, or a
sequence encoding Omp85 or a fragment thereof fused to a sequence
encoding a second protein, and a detectable label which is
associated with said sequence.
[0015] In still another aspect, the invention provides an isolated
antibody which is directed against Omp85 of N. gonorrhoeae or a
fragment thereof.
[0016] In a further aspect, the invention provides an anti-idiotype
antibody specific for the antibody described above.
[0017] In another aspect, the invention provides a diagnostic
reagent comprising the antibody or anti-idiotype antibody described
above and a detectable label.
[0018] In yet another aspect, the invention provides a vaccine
composition comprising an effective amount of a Omp85 protein of N.
gonorrhoeae, a fusion protein or fragment thereof and a
pharmaceutically acceptable carrier. This composition can also
include at least one other antigen or fragment thereof.
[0019] In another aspect, the invention provides a vaccine
composition comprising an effective amount of a nucleic acid
sequence encoding the Omp85 protein of N. gonorrhoeae, a fusion
protein, or a fragment thereof and a suitable nucleic acid delivery
vehicle. This vaccine composition may also be polyvalent.
[0020] In still a further aspect, the invention provides a method
of vaccinating a human or animal against gonococcal infection or
disease comprising administering to said human or animal a
composition comprising an effective amount of at least one of the
compositions described above.
[0021] Another aspect of the present invention includes a method
for diagnosing gonococcal infection or disease in a human or animal
comprising the steps of contacting an Omp85 antigen optionally
associated with a detectable label or a homolog thereof with a
biological sample from a human subject to be diagnosed, wherein the
presence of naturally occurring antibodies to N. gonorrhoeae in
said sample permits the formation of an antigen-antibody complex,
and analyzing said sample for the presence of said complex, which
indicates infection with N. gonorrhoeae.
[0022] Still another aspect of the invention provides a method for
diagnosing gonococcal infection or disease in a human or animal
comprising the steps of: contacting an Omp85 antibody, optionally
associated with a detectable label, with a biological sample from a
human subject to be diagnosed, wherein the presence of naturally
occurring N. gonorrhoeae Omp85 in said sample permits the formation
of an antigen-antibody complex, and analyzing said sample for the
presence of said complex, which indicates infection with N.
gonorrhoeae.
[0023] Yet a further aspect of the invention provides a method for
diagnosing gonococcal infection or disease in a human or animal
comprising the steps of: employing a nucleic acid sequence encoding
all or a portion of an Omp85 antigen or an Omp85 antibody,
optionally associated with a detectable label, as a probe which,
when in contact with a biological sample from a human subject to be
diagnosed, enables detection of infection by hybridization or
amplification of nucleic acid sequences of N. gonorrhoeae Omp85 in
said sample.
[0024] Yet a further aspect of the invention includes a therapeutic
composition useful in treating humans or animals with
non-symptomatic gonococcal infection or symptomatic disease
comprising at least one anti-N. gonorrhoeae Omp85 antibody and a
suitable pharmaceutical carrier.
[0025] In still another aspect, the invention includes a method for
treating non-symptomatic gonococcal infection or symptomatic
disease in a mammalian host comprising administering an effective
amount of the therapeutic composition described above.
[0026] In yet another aspect, the invention provides a kit for
diagnosing infection with N. gonorrhoeae in a human or animal
comprising an Omp85 protein or fragment thereof or an anti-Omp85
antibody or a nucleic acid sequence encoding the protein or
antibody as described above.
[0027] In another aspect, the invention provides a method of
identifying compounds which specifically bind to Omp85 of N.
gonorrhoeae or a fragment thereof, comprising the steps of
contacting said Omp85 protein or fragment with a test compound to
permit binding of the test compound to Omp85; and determining the
amount of test compound which is bound to Omp85.
[0028] In still another aspect, the invention provides a compound
identified by the above method.
[0029] In one aspect, the invention provides an isolated outer
membrane protein of N. meningitidis having an apparent molecular
weight of 85 kDa and characterized by an amino acid sequence of SEQ
ID NO: 4, a fragment, an analog or a homolog thereof. In another
aspect, the invention provides a nucleic acid sequence encoding the
Omp85 of N. meningitidis or a fragment thereof.
[0030] In still another aspect, the invention provides a nucleic
acid molecule comprising a nucleic acid sequence encoding the Omp85
of N. meningitidis or a fragment thereof under the control of
suitable regulatory sequences which direct expression of said Omp
85 or fragment in a selected host cell.
[0031] In yet a further aspect, the invention provides a host cell
transformed with the above described nucleic acid molecule.
[0032] In still a further aspect, the invention provides a method
of recombinantly expressing the Omp85 of N. meningitidis or a
fragment thereof comprising the steps of culturing a recombinant
host cell transformed with a nucleic acid sequence encoding said
protein or fragment under conditions which permit expression of
said protein or peptide.
[0033] In another aspect, the invention provides a method for
preparing an Omp85 protein of N. meningitidis or fragment thereof
comprising chemically synthesizing said protein or fragment.
[0034] In yet another aspect, the invention provides a diagnostic
reagent comprising a nucleic acid sequence encoding Omp85 of N.
meningitidis, isolated from cellular materials with which it is
naturally associated, a sequence complementary thereto, a fragment
thereof, a sequence which hybridizes thereto under stringent
conditions, an allelic variant thereof, a mutant thereof, or a
sequence encoding Omp85 or a fragment thereof fused to a sequence
encoding a second protein, and a detectable label which is
associated with said sequence.
[0035] In still another aspect, the invention provides an isolated
antibody which is directed against Omp85 of N. meningitidis or a
fragment thereof.
[0036] In a further aspect, the invention provides an anti-idiotype
antibody specific for the antibody described above.
[0037] In another aspect, the invention provides a diagnostic
reagent comprising the antibody or anti-idiotype antibody described
above and a detectable label.
[0038] In yet another aspect, the invention provides a vaccine
composition comprising an effective amount of a Omp85 protein of N.
meningitidis, a fusion protein or fragment thereof and a
pharmaceutically acceptable carrier. This composition can also
include at least one other antigen or fragment thereof.
[0039] In another aspect, the invention provides a vaccine
composition comprising an effective amount of a nucleic acid
sequence encoding the Omp85 protein of N. meningitidis, a fusion
protein, or a fragment thereof and a suitable nucleic acid delivery
vehicle. This vaccine composition may also be polyvalent.
[0040] In still a further aspect, the invention provides a method
of vaccinating a human or animal against non-symptomatic
meningococcal infection and symptomatic disease comprising
administering to said human or animal a composition comprising an
effective amount of at least one of the compositions described
above in either a pharmaceutically acceptable carrier or a nucleic
acid delivery system.
[0041] Another aspect of the present invention includes a method
for diagnosing non-symptomatic gonococcal infection or symptomatic
disease in a human or animal comprising the steps of contacting an
Omp85 antigen optionally associated with a detectable label or a
homolog thereof with a biological sample from a human subject to be
diagnosed, wherein the presence of naturally occurring antibodies
to N. meningitidis in said sample permits the formation of an
antigen-antibody complex, and analyzing said sample for the
presence of said complex, which indicates infection with N.
meningitidis.
[0042] Still another aspect of the invention provides a method for
diagnosing non-symptomatic meningococcal infection and symptomatic
disease in a human or animal comprising the steps of: contacting an
Omp85 antibody, optionally associated with a detectable label, with
a biological sample from a human subject to be diagnosed, wherein
the presence of naturally occurring N. meningitidis Omp85 in said
sample permits the formation of an antigen-antibody complex, and
analyzing said sample for the presence of said complex, which
indicates infection with N. meningitidis.
[0043] Yet a further aspect of the invention provides a method for
diagnosing non-symptomatic meningococcal infection and symptomatic
disease in a human or animal comprising the steps of: employing a
nucleic acid sequence encoding all or a portion of an Omp85 antigen
or an Omp85 antibody, optionally associated with a detectable
label, as a probe which, when in contact with a biological sample
from a human subject to be diagnosed, enables detection of
infection by hybridization or amplification of nucleic acid
sequences of N. meningitidis Omp85 in said sample.
[0044] Yet a further aspect of the invention includes a therapeutic
composition useful in treating humans or animals with
non-symptomatic meningococcal infection and symptomatic disease
comprising at least one anti-N. meningitidis Omp85 antibody and a
suitable pharmaceutical carrier.
[0045] In still another aspect, the invention includes a method for
treating non-symptomatic meningococcal infection and symptomatic
disease in a mammalian host comprising administering an effective
amount of the therapeutic composition described above.
[0046] In yet another aspect, the invention provides a kit for
diagnosing infection with N. meningitidis in a human or animal
comprising an Omp85 protein or fragment thereof or an anti-Omp85
antibody or a nucleic acid sequence encoding the Omp85 protein or
antibody, as described above.
[0047] In another aspect, the invention provides a method of
identifying compounds which specifically bind to Omp85 of N.
meningitidis or a fragment thereof, comprising the steps of
contacting said Omp85 protein or fragment with a test compound to
permit binding of the test compound to Omp85; and determining the
amount of test compound which is bound to Omp85.
[0048] In still another aspect, the invention provides a compound
identified by the above method.
[0049] Other aspects and advantages of the present invention are
described further in the following detailed description of the
preferred embodiments thereof, reference being made to the
accompanying figures.
BRIEF DESCRIPTION OF THE DRAWINGS
[0050] FIG. 1 is a photograph of a sodium dodecyl sulfate
polyacrylamide electrophoretic gel (SDS-PAGE) illustrating the
identification of recombinant Omp85 produced by E. coli
DH5a/pOmp85, as described in Example 2. Bacterial cell lysates were
separated by SDS-PAGE, stained with Coomassie Brilliant blue (CBB)
or transferred to membranes and probed with anti-GC-OM serum. From
left to right are E. coli DH5a, E. coli DH5a/pOmp85, and N.
gonorrhoeae strain FA19. The location of Omp85 is indicated.
Prestained molecular mass markers (MW), were indicated in
kilodaltons (kDa).
[0051] FIGS. 2A-2C illustrate the DNA sequence encoding an open
reading frame of the N. gonorrhoeae omp85 (SEQ ID NO: 1) and the
corresponding deduced amino acid sequence of Omp85 (Genbank
accession #U81959) (SEQ ID NO: 2), which is preceded by an
untranslated 5' sequence (SEQ ID NO: 7), and followed by an
untranslated 3' sequence (SEQ ID NO: 8). The nucleotide sequence
begins with the termination codon of a preceding open reading frame
(ORF) that is similar to that of the H. influenzae hypothetical
protein HI0918 and ends with the initiation codon of a downstream
gene similar to ompH of S. typhimurium (Kosk P. et al, J. Biol.
Chem., 264: 18973-18980 (1989)). The nucleotides of the omp85 open
reading frame are numbered on the left. A ribosome binding site
(underlined) precedes the initiation codon of the omp85 ORF. The
omp85 ORF was preceded and followed by rho-independent
transcriptional termination sequences (indicated by lines with
arrows). The Omp85 precursor polypeptide was composed of 792 amino
acids. The amino acid sequence is numbered on the right. A putative
signal peptide cleavage site was identified (indicated by
arrowhead) (Von Heijne, G., Nucl. Acids Res., 14:4683-4690 (1986)).
Cleavage at this site would produce a mature protein having a
predicted molecular weight of 85,842 Da.
[0052] FIG. 3 is a photograph of a Western blot that illustrates
the identification of Omp85 in N. gonorrhoeae strains FA19, FA635,
FA1090, JS1, F62 and MS11LosA and N. meningitidis strains MP78,
MP3, MP81 and HH by Western blot analysis with anti-GC-OM serum. E.
coli DH5a and E. coli DH5a/pOmp85 were used as negative and
positive controls. Prestained molecular mass markers (MW) were
indicated in kDa.
[0053] FIG. 4 is a photograph of a Southern blot that illustrates
the identification of omp85 in genomic DNA from N. gonorrhoeae FA19
and N. meningitidis strains MP3, MP73, MP81 and HH digested with
restriction endonucleases (HincII, EcoRI, PstI, ClaI) and probed
with a 688 by fragment of gonococcal omp85. This fragment was used
as a positive control in the first lane. Molecular weight markers
are indicated on the left in kilobase pairs. E. coli DH5a was used
as a negative control.
[0054] FIG. 5 illustrates the amino acid sequence of N.
meningitidis Omp85 (Genbank accession #AF021045) (SEQ ID NO: 4)
compared to that of N. gonorrhoeae Omp85 (SEQ ID NO: 2). On the top
line is the N. meningitidis Omp85 amino acid sequence. Below it are
the amino acids that are different in the N. gonorrhoeae Omp85.
Amino acids that are absent in the gonococcal Omp85 are indicated
by stars Amino acids that are identical in the Omp85 homologs of N.
meningitidis, N. gonorrhoeae, H. influenzae (D-15-Ag) and P.
multocida (Oma87) are underlined. The amino acids of the
meningococcal Omp85 are numbered on the right.
[0055] FIG. 6 is a photograph of a Western blot that illustrates
the identification of Omp85 in N. gonorrhoeae strains FA19, FA635,
FA1090, JS1, F62 and MS11LosA and N. meningitidis strains MP78,
MP3, MP81 and HH by Western blot analysis with anti-Omp85, as
described in Example 7. E. coli DH5a, E. coli DH5a/pOmp85 and E.
coli DH5a/pMCOmp85 were used as negative and positive controls.
Prestained molecular mass markers (MW) were indicated in kDa.
[0056] FIG. 7A is a photograph of a Western blot that illustrates
the distribution of Omp85 in pathogenic and commensal Neisseriae
(relationship areas A, B, C, and D) and related Gram negative
bacteria: N. gonorrhoeae FA19 (A), Neisseria pharyngis (A),
Neisseria cinerea (A), Neisseria lactamica (B), Neisseria mucosae
(B), Neisseria flavescens (C), Neisseria animalis (C), Neisseria
denitrificans (C), Moraxella catarrhalis (D), Klebsiella
pneumoniae, Pseudomonas aeruginosa, and N. meningitidis HH (A), as
described in Example 7. E. coli DH5a and E. coli DH5a/pOmp85, were
used as negative and positive controls. Prestained molecular mass
markers (MW) were indicated in kDa.
[0057] FIG. 7B is a photograph of a Western blot that illustrates
the distribution of Omp85 in N. gonorrhoeae FA19, Salmonella
typhimurium, Shigella flexneri, E. coli strains 35150
(enterohemorrhagic--EHEC), 35401 (enterotoxigenic--ETEC), 43887
(enteropathogenic--EPEC), 43892 (enteroinvasive--EIEC) and N.
meningitidis, as described in Example 7. E. coli DH5a and E. coli
DH5a/pOmp85 were used as negative and positive controls. Prestained
molecular mass markers (MW) were indicated in kDa.
[0058] FIG. 8 is a bar graph showing the results of a gonococcal
cell adherence assay performed with no antibody (black bars), and
with Fab fragments prepared from antisera to: MS11 Omp 85, MS11
hyperimmune sera to bovine serum albumin (MS11BSA), MS11
hyperimmune serum to normal rabbit serum (MS11NRS), FA19 Omp 85,
FA19BSA and FA19NRS at concentrations of 1, 10 and 100 .mu.g/ml
(see key). The assay was performed as described in Example 8.
DETAILED DESCRIPTION OF THE INVENTION
[0059] The present invention provides novel, characterized, outer
surface membrane proteins, referred to as Omp85, from N.
gonorrhoeae and N. meningitidis. These novel antigens, fragments
thereof, antibodies developed thereto, the nucleic acid sequences
encoding same, and the use of such antigens, antibodies and nucleic
acid sequences provide diagnostic, therapeutic and prophylactic
compositions and methods for the treatment or prevention of
gonococcal and meningococcal infections, particularly
non-symptomatic infections, and diseases.
I. The Omp85 Antigens of the Invention
[0060] To identify the previously uncharacterized N. gonorrhoeae
outer membrane proteins, an N. gonorrhoeae genomic library was
screened with an antiserum raised against purified isolated
gonococcal outer membranes. The gonococcal gene, omp85, was
identified that encodes a 792 amino acid outer membrane protein,
Omp85, of N. gonorrhoeae having an apparent molecular weight of 85
kDa and characterized by the amino acid sequence of FIGS. 2A-2C and
SEQ ID NO: 2. Omp85 has a typical signal peptide and a
carboxyl-terminal phenylalanine characteristic of outer membrane
proteins. Southern analysis demonstrated that the omp85 gene was
present as a single copy in N. gonorrhoeae and N. meningitidis. PCR
amplification was used to obtain a clone of the N. meningitidis
omp85 homolog. The genes encoding the N. gonorrhoeae and N.
meningitidis Omp85 proteins have been cloned and sequenced. The
omp85 gene and its product in both N. gonorrhoeae and N.
meningitidis are characterized in FIGS. 2 and 5 below (SEQ ID NOS:
1-4).
[0061] The nucleic acid sequences encoding the Omp85 proteins and
the structures of the proteins themselves are described below.
Where in this specification, protein and/or DNA sequences are
defined by their percent homologies or identities to identified
sequences, the algorithms used to calculate the percent identities
or percent similarities include the following: the Smith-Waterman
algorithm (J. F. Collins et al, 1988, Comput. Appl. Biosci.,
4:67-72; J. F. Collins et al, Molecular Sequence Comparison and
Alignment, (M. J. Bishop et al, eds.) In Practical Approach Series:
Nucleic Acid and Protein Sequence Analysis XVIII, IRL Press:
Oxford, England, UK (1987) pp. 417), and the BLAST and FASTA
programs (E. G. Shpaer et al, Genomics, 38:179-191 (1996)),
including the BLAST2 program (S. D. Altschul et al, J. Mol. Biol.,
215:403-407 (1990)). These references are incorporated herein by
reference.
[0062] A. Nucleic Acid Sequence
[0063] The present invention provides bacterial nucleic acid
sequences encoding omp85 sequences of N. gonorrhoeae and N.
meningitidis. The nucleic acid sequences of this invention are
isolated from cellular materials with which they are naturally
associated. The DNA sequence of the N. gonorrhoeae omp85 (SEQ ID
NO: 1) and the corresponding deduced amino acid sequence of Omp85
(Genbank accession #U81959) (SEQ ID NO: 2) were obtained as
described in Example 2 and in FIGS. 2A-2C. The nucleotide sequence
begins with the termination codon of a preceding ORF that is
similar to that of the H. influenzae hypothetical protein HI0918
and ends with the initiation codon of a downstream gene similar to
ompH of S. typhimurium [(Kosk P. et al, J. Biol. Chem., 264:
18973-18980 (1989)]). A ribosome binding site precedes the
initiation codon of the omp85 ORF. The omp85 ORF was preceded and
followed by rho-independent transcriptional termination sequences.
The Omp85 precursor polypeptide was composed of 792 amino acids. A
putative signal peptide cleavage site was identified (indicated by
arrowhead) (Von Heijne, G., Nucl. Acids Res., 14:4683-4690 (1986)).
Cleavage at this site produces a mature protein having a predicted
molecular weight of 85,842 Da.
[0064] The DNA sequence of the N. meningitidis omp85 (SEQ ID NO: 3)
and the corresponding deduced amino acid sequence of Omp85 (Genbank
accession #AF021045) (SEQ ID NO: 4) were obtained as described in
Example 3. FIG. 5 shows the comparison between the sequences of the
two Omp85 proteins, as well as the similarities between the Omp85
homologs of N. meningitidis, N. gonorrhoeae, H. influenzae
(D-15-Ag) and P. multocida (Oma87).
[0065] In addition to the full-length nucleic acid sequences
encoding the Omp85 proteins provided herein, the specification also
includes fragments of these omp85 genes. Preferably, such fragments
are characterized by encoding a biologically active portion of
Omp85, e.g., an epitope. Alternatively, other non-epitopic
fragments may be useful as probes in diagnostic or research use.
Generally, these oligonucleotide fragments are at least 10, or at
least 15 consecutive nucleotides in length. However,
oligonucleotide fragments of varying sizes may be selected as
desired. Such fragments may be used for such purposes as performing
polymerase chain reaction (PCR), e.g., on a biopsied tissue sample.
For example, useful fragments of omp85 DNA and corresponding
sequences comprise sequences occurring between nucleotides 2161
through 2208 of SEQ ID NO: 1 and nucleotides 2161 and 2218 of SEQ
ID NO: 3. Other useful fragments may be readily obtained by one of
skill in the art by resort to conventional DNA sequencing
techniques applied to the sequences disclosed herein.
[0066] The DNA sequences of SEQ ID NOS: 1 and 3 permit one of skill
in the art to readily obtain the corresponding anti-sense strands
of these DNA sequences. Further, using known techniques, one of
skill in the art can readily obtain additional genomic and cDNA
sequences which flank the illustrated DNA sequences or the
corresponding RNA sequences, as desired. Similarly the availability
of SEQ ID NOS: 1 and 3 of this invention permits one of skill in
the art to obtain other species Omp85 analogs, and fragments
thereof, by use of the nucleic acid sequences of this invention as
probes in a conventional technique, e.g., polymerase chain
reaction. Allelic variants of these sequences within a species
(i.e., sequences containing some individual nucleotide differences
from a more commonly occurring sequence within a species, but which
nevertheless encode the same protein or a protein with the same
function) such as other variants of Omp85 (SEQ ID NOS: 2 and 4) may
also be readily obtained given the knowledge of these nucleic acid
sequences provided by this invention.
[0067] The present invention further encompasses nucleic acid
sequences capable of hybridizing under stringent conditions (see,
J. Sambrook et al, Molecular Cloning: A Laboratory Manual, 2d ed.,
Cold Spring Harbor Laboratory (1989)) to the sequences of SEQ ID
NOS: 1 and 3, their anti-sense strands, or biologically active
fragments thereof. An example of a highly stringent hybridization
condition is hybridization at 2.times.SSC at 65.degree. C.,
followed by a washing in 0.1.times.SSC at 65.degree. C. for an
hour. Alternatively, an exemplary highly stringent hybridization
condition is in 50% formamide, 4.times.SSC at 42.degree. C.
Moderately high stringency conditions may also prove useful, e.g.,
hybridization in 4.times.SSC at 55.degree. C., followed by washing
in 0.1.times.SSC at 37.degree. C. for an hour. An alternative
exemplary moderately high stringency hybridization condition is in
50% formamide, 4.times.SSC at 30.degree. C.
[0068] According to the invention, the nucleic acid sequences may
be modified. Utilizing the sequence data of SEQ ID NOS: 1 and 3, it
is within the skill of the art to obtain other synthetically or
recombinantly-prepared polynucleotide sequences, or modified
polynucleotide sequences, encoding the full-length proteins or
useful fragments of the invention. For example, one of skill may
employ preferred or "preference" codons for expression of the
sequence in selected host cells; thus SEQ ID NOS: 1 and 3 may be
modified to contain different nucleotide triplets which encode the
same amino acid as encoded by SEQ ID NOS: 1 and 3. Such
modifications made at the nucleic acid level include, for example,
modifications to the nucleotide sequences which are silent or which
change the amino acids, e.g. to improve expression or secretion of
the protein. Also included are allelic variations, caused by the
natural degeneracy of the genetic code.
[0069] Also encompassed by the present invention are mutants of the
omp85 sequences, including 5', 3' or internal deletions, which
encode proteins that substantially retain the antigenicity of the
full-length Omp85 or other proteins or fragments. Such truncated,
or deletion, mutants may be expressed by modified nucleic acid
sequences for the purpose of affecting the activity of the
full-length or wild-type protein.
[0070] As described in more detail below, these nucleic acid
sequences are useful for a variety of diagnostic, prophylactic and
therapeutic uses. Advantageously, the nucleic acid sequences are
useful in the development of diagnostic probes and antisense probes
for use in the detection and diagnosis of infections, particularly
non-symptomatic infection, and diseases caused by these Neisseriae
pathogens and by related pathogens discussed above by utilizing a
variety of known nucleic acid assays, e.g., Northern and Southern
blots, polymerase chain reaction (PCR), and other assay techniques
known to one of skill in the art. The nucleic acid sequences of
this invention are also useful in the production of Omp 85 proteins
and homologs as well as a variety of fusion or other synthetic
proteins.
[0071] The nucleotide sequences of the invention may be readily
synthesized or may be isolated by conventional uses of polymerase
chain reaction or cloning techniques such as those described herein
and in conventional texts such as Sambrook et al, cited above. For
example, the nucleic acid sequences of the antigen of this
invention may be prepared or isolated from genomic libraries using
DNA primers and probes and PCR techniques. These sequences,
fragments thereof, modifications thereto and the full-length
sequences may be constructed recombinantly using conventional
genetic engineering or chemical synthesis techniques or PCR, and
the like by utilizing the information provided herein. Further,
such nucleic acid sequences may be conventionally labeled for
diagnostic use. Alternatively for use as therapeutic or vaccine
components, the nucleic acid sequences of this invention may be
admixed with a variety of pharmaceutically acceptable carriers,
e.g., saline, liposomes, etc. or incorporated into nucleic acid
molecules, e.g., plasmids under the regulatory control of sequences
which direct expression of the encoded protein in a selected host
cell. The nucleic acid sequences may also be delivered to a host as
"naked" DNA or in a gene delivery vehicle, such as a recombinant
virus, all as described in detail below.
[0072] B. Protein Sequences
[0073] The present invention also provides Omp85 proteins and
peptides of this invention. These proteins are free from
association with other contaminating proteins or materials with
which they are found in nature. The Neisseriae Omp85 antigen has a
relative molecular mass of 85 kDa as measured by Western immunoblot
(See Example 2 and FIGS. 2A-2C). In one embodiment, the invention
provides a gonococcal Omp85 antigen (SEQ ID NO:2) polypeptide of
about 792 amino acids, with a signal peptide, having a predicted
molecular weight of 85,842 daltons.
[0074] The meningococcal omp85 was found to encode a 797 amino acid
polypeptide with a predicted molecular weight of 88.5 kDa (FIG. 5).
Between amino acid residues 720 and 745, the menigococcal Omp85
varied substantially from gonococcal Omp85, including the insertion
of five additional amino acids. The deduced amino acid sequence
(SEQ ID NO: 4) of N. meningitidis Omp85 was revealed by sequence
analysis to be 95% identical to N. gonorrhoeae Omp85 and 98%
similar to gonococcal Omp85 using the BLAST2 algorithm.
[0075] The similarities of these two Omp85 proteins to proteins of
other microorganisms provide evidence of an immunological role
played by these proteins, as well as other potential roles. The
D-15 protective surface antigen (D-15-Ag) of Haemophilus influenzae
and the Oma87 of Pasteurella multocida are the only bacterial
proteins, which have been previously described, that are similar to
the Omp85 amino acid sequence (SEQ ID NO: 2). This similarity
suggested that these proteins played an important role in
host-pathogen interactions and have an important function in
pathogenesis. The importance of these Omp85 proteins in
pathogenesis and immunobiology was demonstrated by the fact that
antibody to similar proteins in H. influenzae and P. multocida were
protective. The similarities suggest that the Neisseriae Omp85
proteins are likely important immunological targets of the host
immune response.
[0076] Western blot analysis demonstrated proteins similar to Omp85
in all of the Neisseriae tested with anti-Omp85 in three Neisseriae
relationship areas. Area A contains the frank pathogens N.
gonorrhoeae and N. meningitidis and opportunistic organisms known
to cause severe human diseases such as N. pharyngis and N. cinerea.
Area B contains species, such as N. mucosae and N. lactamica,
typically found in the human nasopharynx which are able to cause
opportunistic infections in debilitated hosts. Area C consists of
commensal/saprophytic organisms, such as N. flavescens, N. animalis
and N. denitricans, which generally do not cause human
infections.
[0077] All Neisseriae species colonize mucosal surfaces. The
presence of Omp85-like proteins in numerous pathogenic and
commensal organisms suggests it may be involved in establishing or
maintaining colonization. The identification of Omp85 proteins in a
number of pathogenic and commensal organisms provides evidence that
the Omp85 proteins provide functions involved in establishing or
maintaining colonization.
[0078] Database searches identified genes in a number of pathogens
which encode hypothetical proteins similar to Omp85, including
genes in B. abortus, H. pylori, and B. burgdorferi. The proteins
encoded by these genes have not yet been characterized. A search of
the Omp85 amino acid sequence against the GenBank data base
resulted in the identification of a cyanobacterium protein (Kaneto
T. et al, DNA.sub.--Res., 3: 109-136 (1996)) with 35% similarity to
the gonococcal Omp85. The cyanobacterium protein was named IAP75
because of its similarity to the 75 kDa chloroplast import
associated protein, IAP75 (Schnell D J et al, Science, 266:
1007-1011 (1994)). The chloroplast IAP75 was located in the outer
membrane of chloroplasts and was one of four outer membrane
components of a complex that transports polypeptides. This
suggested that Omp85 might be part of a similar transport
complex.
[0079] The sequences of other proteins from the chloroplast import
associated complex were searched against the Gonococcal Genome
Sequencing Project Data Base (Dyer and Rowe, 1997). Sequences
similar to the chloroplast IAP34 protein (Kessler F. et al,
Science, 266: 1035-1039 (1994)) were identified in the gonococcal
genome. IAP34 is believed to be a GTP-binding protein and the
sequences of highest similarity to the gonococcal homolog were in
regions identified as GTP-binding protein motifs.
Surface-crosslinkage studies were performed to determine if Omp85
might participate in a system analogous to the IAP complex (data
not shown). Studies using the reversible crosslinker DTBP, which
crosslinks proteins that are within 11.9A of each other (Newhall W
J. et al, Infect. Immun., 28: 785-791 (1980)), showed that Omp85
crosslinked with up to five other outer membrane proteins, one of
.about.34 kDa (IAP34 homolog) (data not shown). These data, which
confirmed Omp85 was exposed on the bacterial surface, support the
role for Omp85 of participating in a complex analogous to that of
the chloroplast IAP complex. Further characterization of proteins
associated with Omp85 in the outer membrane may provide evidence of
additional biological functions of these Omp85 proteins.
[0080] One of skill in the art using conventional techniques, such
as PCR, may readily use the Omp85 sequences provided herein to
identify and isolate other similar proteins. Such methods are
routine and not considered to require undue experimentation, given
the information provided herein.
[0081] Antigens of this invention may be characterized by
immunological measurements including, without limitation, Western
blot, macromolecular mass determinations by biophysical
determinations, such as SDS-PAGE/staining, high pressure liquid
chromatography (HPLC) and the like, antibody recognition assays,
T-cell recognition assays, major histocompatibility complex (MHC)
binding assays, and assays to infer immune protection or immune
pathology by adoptive transfer of cells, proteins or
antibodies.
[0082] The Omp85 outer membrane antigens of this invention (as well
as its naturally occurring variants or analogs in other species)
may be isolated in the form of a complete intact protein, or a
polypeptide or fragment thereof. In one embodiment, Omp85 is
isolated by immunoblot procedures according to its respective
molecular mass, as described below in the examples. Such isolation
provides the antigen in a form substantially free from other
proteinaceous and non-proteinaceous materials of the microorganism.
The molecules comprising the polypeptides and antigens of this
invention may be isolated and further purified using any of a
variety of conventional methods including, but not limited to:
liquid chromatography such as normal or reverse phase, using HPLC,
FPLC and the like; affinity chromatography (such as with inorganic
ligands or monoclonal antibodies); size exclusion chromatography;
immobilized metal chelate chromatography; gel electrophoresis; and
the like. One of skill in the art may select the most appropriate
isolation and purification techniques without departing from the
scope of this invention.
[0083] Alternatively, the amino acid sequences of the proteins of
this invention may be produced recombinantly following conventional
genetic engineering techniques (see e.g., Sambrook et al, cited
above and the detailed description of making the proteins
below).
[0084] i. Analogs/Modified Antigen
[0085] Also included in the invention are analogs, or modified
versions, of the Omp85 protein or fragments provided herein.
Typically, such analogs differ from the specifically identified
proteins by only one to four codon changes. Examples include
polypeptides with minor amino acid variations from the illustrated
partial amino acid sequence of, for example, the gonococcal Omp85
(SEQ ID NO: 2), in particular, conservative amino acid
replacements. Conservative replacements are those that take place
within a family of amino acids that are related in their side
chains and chemical properties. Also provided are homologs of the
proteins of the invention which are characterized by having at
least 80% identity with SEQ ID NO:2 or SEQ ID NO: 4. Also included
in this invention are homologs having at least 85% identity with
SEQ ID NO: 2 or SEQ ID NO: 4. Homologs having at least 90% identity
with either SEQ ID NO: 2 or SEQ ID NO: 4 are also encompassed by
this invention. Homologs having at least 95% identity with either
SEQ ID NO: 2 or SEQ ID NO: 4 are also encompassed by this
invention. Also provided are homologs of the proteins of the
invention which are characterized by having at least 85% homology
with SEQ ID NO:2 or SEQ ID NO: 4. Also included in this invention
are homologs having at least 90% homology with SEQ ID NO: 2 or SEQ
ID NO: 4. Homologs having at least 95% homology with either SEQ ID
NO: 2 or SEQ ID NO: 4 are also encompassed by this invention.
Homologs having at least 99% homology with either SEQ ID NO: 2 or
SEQ ID NO: 4 are also encompassed by this invention. The algorithms
used for these calculations are identified above. Based on the
sequence information provided herein, one of skill in the art can
readily obtain full-length homologs and analogs from other
bacterial species.
[0086] An antigen of the present invention may also be modified to
increase its immunogenicity. For example, the antigen may be
coupled to chemical compounds or immunogenic carriers, provided
that the coupling does not interfere with the desired biological
activity of either the antigen or the carrier. For a review of some
general considerations in coupling strategies, see Antibodies, A
Laboratory Manual, Cold Spring Harbor Laboratory, ed. E. Harlow and
D. Lane (1988). Useful immunogenic carriers known in the art,
include, without limitation, keyhole limpet hemocyanin (KLH);
bovine serum albumin (BSA), ovalbumin, purified protein derivative
of tuberculin (PPD); red blood cells; tetanus toxoid; cholera
toxoid; agarose beads; activated carbon; or bentonite. Useful
chemical compounds for coupling include, without limitation,
dinitrophenol groups and arsonilic acid. One of skill in the art
may readily select other appropriate immunogenic carriers or
coupling agents. The antigen may also be modified by other
techniques, such as denaturation with heat and/or SDS.
[0087] ii. Fragments/Deletion Mutants
[0088] Further encompassed by this invention are additional
fragments of the Omp85 polypeptides and peptides identified herein.
Such fragments are desirably characterized by having a biological
activity similar to that displayed by the complete protein,
including, e.g., the ability to induce antibodies which can
interfere with the binding of the pathogen to its cellular targets
(see Example 8). These fragments may be designed or obtained in any
desired length, including as small as about 5-8 amino acids in
length up to fragments encompassing just short of the entire
protein. Such fragments may represent consecutive amino acids in
the protein sequence or they may represent conformational sites of
the protein. Such a fragment may represent an epitope or
conformational epitope of the protein.
[0089] The Omp85 proteins (SEQ ID NOS:2 and 4) of the invention may
be modified to create deletion mutants, for example, by truncation
at the amino or carboxy termini, or by elimination of one or more
amino acids. Deletion mutants are also encompassed by this
invention, as are the DNA sequences encoding them.
[0090] In yet another embodiment, the Omp85 peptides or
polypeptides of this invention may be in the form of a multiple
antigenic peptide ("MAP", also referred to as an octameric lysine
core peptide) construct. Such a construct may be designed employing
the MAP system described by Tam, Proc. Natl. Acad. Sci. USA,
85:5409-5413 (1988). This system makes use of a core matrix of
lysine residues onto which multiple copies of the same protein or
peptide of the invention are synthesized as described (D. Posnett
et al., J. Biol. Chem., 263(4):1719-1725 (1988); J. Tarn,
"Chemically Defined Synthetic Immunogens and Vaccines by the
Multiple Antigen Peptide Approach", Vaccine Research and
Developments, Vol. 1, ed. W. Koff and H. Six, pp. 51-87 (Marcel
Deblau, Inc., New York 1992)). Each MAP contains multiple copies of
only one peptide.
[0091] Still other modified fragments of Omp85 may be prepared by
any number of now conventional techniques to improve production
thereof, to enhance protein stability or other characteristics,
e.g. binding activity or bioavailability, or to confer some other
desired property upon the protein. Other useful fragments of these
polypeptides may be readily prepared by one of skill in the art
using known techniques, such as deletion mutagenesis and
expression.
[0092] iii. Fusion or Multimeric Proteins and Compositions
[0093] The Omp85 protein of the present invention, or fragments of
it, may also be constructed, using conventional genetic engineering
techniques as part of a larger and/or multimeric protein or protein
compositions. Antigens of this invention may be in combination with
outer surface proteins or other proteins or antigens of other
pathogens, such as those identified above, or various fragments of
the antigens described herein may be in combination with each
other. In such combination, the antigen may be in the form of a
fusion protein. The antigen of the invention may be optionally
fused to a selected polypeptide or protein derived from other
microorganisms. For example, an antigen or polypeptide of this
invention may be fused at its N-terminus or C-terminus to a
polypeptide from another pathogen or to more than one polypeptide
in sequence. Polypeptides which may be useful for this purpose
include polypeptides identified by the prior art.
[0094] Still another fusion protein of this invention is provided
by expressing the DNA molecule formed by the omp85 DNA sequence or
a fragment thereof fused to DNA fragments that are homologous
(between about 25-95% identity) to Omp85. One example of such a
protein comprises the amino acid sequence of SEQ ID NO: 2 to which
is fused amino acid fragments that are up to 95% identical to that
sequence, e.g., from SEQ ID NO: 4, or from any of the
above-described homologous proteins. These fragments may be
inserted in any order and may contain repeated sequences. The fused
fragments may produce a large DNA molecule which expresses a
protein which may stimulate a variety of antibody
specificities.
[0095] These fusion proteins comprising multiple polypeptides of
this invention are constructed for use in the methods and
compositions of this invention. These fusion proteins or multimeric
proteins may be produced recombinantly, or may be synthesized
chemically. They also may include the polypeptides of this
invention fused or coupled to moieties other than amino acids,
including lipids and carbohydrates. Further, antigens of this
invention may be employed in combination with other vaccinal agents
described by the prior art, as well as with other species of
vaccinal agents derived from other microorganisms. Such proteins
are useful in the prevention, treatment and diagnosis of diseases
caused by a wide spectrum of Neisseriae isolates.
[0096] A protein composition which may be a preferred alternative
to the fusion proteins described above is a cocktail (i.e., a
simple mixture) containing different Omp85 proteins or fragments,
optionally mixed with different antigenic proteins or peptides of
other pathogens. Such mixtures of these proteins or antigenic
fragments thereof are likely to be useful in the generation of
desired antibodies to a wide spectrum of Neisseriae isolates.
[0097] iv. Salts
[0098] An antigen of the present invention may also be used in the
form of a pharmaceutically acceptable salt. Suitable acids and
bases which are capable of forming salts with the polypeptides of
the present invention are well known to those of skill in the art,
and include inorganic and organic acids and bases.
II. Methods of Making Antigens and Nucleic Acid Sequences of the
Invention
[0099] A. Expression In Vitro
[0100] To produce recombinant Omp85 or peptide fragments of this
invention, the DNA sequences of the invention are inserted into a
suitable expression system. Desirably, a recombinant molecule or
vector is constructed in which the polynucleotide sequence encoding
the selected protein, e.g., Omp85, is operably linked to a
heterologous expression control sequence permitting expression of
the protein. Numerous types of appropriate expression vectors are
known in the art for protein expression, by standard molecular
biology techniques. Such vectors are selected from among
conventional vector types including insects, e.g., baculovirus
expression, or yeast, fungal, bacterial or viral expression
systems. Other appropriate expression vectors, of which numerous
types are known in the art, can also be used for this purpose.
Methods for obtaining such expression vectors are well-known. See,
Sambrook et al, Molecular Cloning. A Laboratory Manual, 2d edition,
Cold Spring Harbor Laboratory, New York (1989); Miller et al,
Genetic Engineering, 8:277-298 (Plenum Press 1986) and references
cited therein.
[0101] Suitable host cells or cell lines for transfection by this
method include bacterial cells. For example, the various strains of
E. coli, e.g., HB101, MC1061, and strains used in the following
examples, are well-known as host cells in the field of
biotechnology. Various strains of B. subtilis, Pseudomonas,
Streptomyces, and other bacilli and the like are also employed in
this method.
[0102] Mammalian cells, such as human 293 cells, Chinese hamster
ovary cells (CHO), the monkey COS-1 cell line or murine 3T3 cells
derived from Swiss, Balb-c or NIH mice are used. Another suitable
mammalian cell line is the CV-1 cell line. Still other suitable
mammalian host cells, as well as methods for transfection, culture,
amplification, screening, production, and purification are known in
the art. (See, e.g., Gething and Sambrook, Nature, 293:620-625
(1981), or alternatively, Kaufman et al, Mol. Cell. Biol.,
5(7):1750-1759 (1985) or Howley et al, U.S. Pat. No. 4,419,446).
Many strains of yeast cells known to those skilled in the art are
also available as host cells for expression of the polypeptides of
the present invention. Other fungal cells may also be employed as
expression systems. Alternatively, insect cells such as Spodoptera
frugipedera (Sf9) cells may be used.
[0103] Thus, the present invention provides a method for producing
recombinant Omp85 proteins, which involves transfecting, e.g., by
conventional means such as electroporation, a host cell with at
least one expression vector containing a polynucleotide of the
invention under the control of a transcriptional regulatory
sequence. The transfected or transformed host cell is then cultured
under conditions that allow expression of the protein. The
expressed protein is recovered, isolated, and optionally purified
from the cell (or from the culture medium, if expressed
extracellularly) by appropriate means known to one of skill in the
art.
[0104] For example, the proteins are isolated in soluble form
following cell lysis, or extracted using known techniques, e.g., in
guanidine chloride. If desired, the proteins or fragments of the
invention are produced as a fusion protein. Such fusion proteins
are those described above. Alternatively, for example, it may be
desirable to produce fusion proteins to enhance expression of the
protein in a selected host cell, to improve purification, or for
use in monitoring the presence of the desired protein, e.g., Omp85,
in tissues, cells or cell extracts. Suitable fusion partners for
the proteins of the invention are well known to those of skill in
the art and include, among others, .beta.-galactosidase,
glutathione-S-transferase, poly-histidine and maltose binding
protein.
[0105] B. Expression In Vivo
[0106] Alternatively, where it is desired that the Omp85 (whether
full-length or a fragment) be expressed in vivo, e.g., to induce
antibodies, or alternatively where the omp85 is to be employed as a
DNA vaccine, an appropriate vector for delivery is readily selected
by one of skill in the art. Exemplary vectors for in vivo gene
delivery are readily available from a variety of academic and
commercial sources, and include, e.g., adeno-associated virus
(International patent application No. PCT/US91/03440), adenovirus
vectors (M. Kay et al, Proc. Natl. Acad. Sci. USA, 91:2353 (1994);
S. Ishibashi et al, J. Clin. Invest., 92:883 (1993)), or other
viral vectors, e.g., various poxviruses, vaccinia, etc. Methods for
insertion of a desired gene, e.g., Omp85, and obtaining in vivo
expression of the encoded protein, are well known to those of skill
in the art.
III. Antibodies of the Invention
[0107] The present invention also provides antibodies capable of
recognizing and binding the isolated, or modified, or multimeric
antigens of this invention, including antibodies derived from
mixtures of such antigens or fragments thereof. Certain of the
antibodies of this invention may be specific to the N. gonorrhoeae
or N. meningitidis Omp85 proteins, by binding to epitopes on the
proteins which differ from the former species to the latter
species. For example, an antibody specific for N. gonorrhoeae may
bind an epitope on SEQ ID NO: 2 which is not present in SEQ ID NO:
4, or vice versa. Thus, an N. gonorrhoeae Omp85-specific antibody
is defined herein as an antibody that binds an Omp85 antigen of N.
gonorrhoeae only. An N. meningitidis Omp85-specific antibody is
defined herein as an antibody that binds an Omp85 antigen of N.
meningitidis only. Alternatively, certain antibodies to these
proteins may bind an epitope present on both the N. gonorrhoeae and
N. meningitidis Omp85 proteins. Still other antibodies of this
invention may bind an epitope on N. gonorrhoeae and N. meningitidis
Omp85, and the same epitope on the other homologous proteins in
homologous or heterologous species of bacteria having homologous
proteins (described in Part I, B above). All of these antibodies
are encompassed by this invention.
[0108] These antibodies are useful in diagnosis of gonococcal and
meningococcal infection (non-symptomatic) as well as symptomatic
diseases, caused by N. gonorrhoeae, N. meningitidis or other
Neisseriae species, and in therapeutic compositions for treating
humans and/or animals that test positive for infection, or, prior
to testing, exhibit symptoms of such diseases. The antibodies are
useful in diagnosis alone or in combination with antibodies to
other antigens of this invention, as well as antibodies to other
known antigens from homologous or completely heterologous species
of microorganism. These antibodies are also useful in passive
vaccine compositions, which vaccines may also be polyvalent, by
containing antibodies to antigens of other microorganisms as well
as antibodies to the Omp85 proteins of this invention.
[0109] The antibodies of this invention are generated by
conventional means utilizing the isolated, recombinant or modified
antigens of this invention, or mixtures of such antigens or
antigenic fragments. For example, polyclonal antibodies are
generated by conventionally stimulating the immune system of a
selected animal or human with the isolated antigen or mixture of
antigenic proteins or peptides of this invention, allowing the
immune system to produce natural antibodies thereto, and collecting
these antibodies from the animal or human's blood or other
biological fluid.
[0110] For example, an antibody according to the invention is
produced by administering to a vertebrate host the antigen or
antigenic composition of this invention, e.g., Omp85. Preferably a
recombinant version of Omp85 (rOmp85) or an Omp85 MAP is used as an
immunogen. A suitable polyclonal antibody against the Omp85 antigen
may be generated as antisera, such as the Omp85 antisera employed
in the examples herein.
[0111] Thus, an antibody of the invention is isolated by affinity
purifying antiserum generated during an infection of a mammal,
e.g., a mouse, with N. gonorrhoeae or N. meningitidis, using as
immunoabsorbant the Omp85 antigen identified herein. Similarly, an
antibody of the invention is isolated by immunizing mice with a
purified, recombinant antigen of this invention, or a purified,
isolated Omp85 protein of native origin.
[0112] Monoclonal antibodies (MAbs) directed against Omp85 are also
generated. Hybridoma cell lines expressing desirable MAbs are
generated by well-known conventional techniques, e.g. Kohler and
Milstein and the many known modifications thereof. Similarly
desirable high titer antibodies are generated by applying known
recombinant techniques to the monoclonal or polyclonal antibodies
developed to these antigens (see, e.g., PCT Patent Application No.
PCT/GB85/00392; British Patent Application Publication No.
GB2188638A; Amit et al., Science, 233:747-753 (1986); Queen et al.,
Proc. Nat'l. Acad. Sci. USA, 86:10029-10033 (1989); PCT Patent
Application No. WO90/07861; and Riechmann et al., Nature,
332:323-327 (1988); Huse et al, Science, 246:1275-1281
(1988)a).
[0113] Given the disclosure contained herein, one of skill in the
art may generate chimeric, humanized or fully human antibodies
directed against Omp85 or antigenic fragments thereof by resort to
known techniques by manipulating the complementarity determining
regions of animal or human antibodies to the antigen of this
invention. See, e.g., E. Mark and Padlin, "Humanization of
Monoclonal Antibodies", Chapter 4, The Handbook of Experimental
Pharmacology, Vol. 113, The Pharmacology of Monoclonal Antibodies,
Springer-Verlag (June, 1994).
[0114] Alternatively, the antigens are assembled as multi-antigenic
complexes (see, e.g., European Patent Application 0339695,
published Nov. 2, 1989) or as simple mixtures of antigenic
proteins/peptides and employed to elicit high titer antibodies
capable of binding the selected antigen(s) as it appears in the
biological fluids of an infected animal or human.
[0115] Further provided by the present invention are anti-idiotype
antibodies (Ab2) and anti-anti-idiotype antibodies (Ab3). Ab2 are
specific for the target to which anti-Omp85 antibodies of the
invention bind and Ab3 are similar to Omp85 antibodies (Ab1) in
their binding specificities and biological activities (see, e.g.,
M. Wettendorff et al., "Modulation of anti-tumor immunity by
anti-idiotypic antibodies." in Idiotypic Network and Diseases, ed.
by J. Cerny and J. Hiernaux J, Am. Soc. Microbiol., Washington
D.C.: pp. 203-229, (1990)). These anti-idiotype and
anti-anti-idiotype antibodies are produced using techniques well
known to those of skill in the art. Such anti-idiotype antibodies
(Ab2) can bear the internal image of Omp85 or fragments thereof and
are thus useful for the same purposes as Omp85 or the
fragments.
[0116] In general, polyclonal antisera, monoclonal antibodies and
other antibodies which bind to the selected antigen (Ab1) are
useful to identify epitopes of Omp85 to separate Omp85 and analogs
thereof from contaminants in living tissue (e.g., in
chromatographic columns and the like), and in general as research
tools and as starting material essential for the development of
other types of antibodies described above. Anti-idiotype antibodies
(Ab2) are useful for binding the same target and thus may be used
in place of the original antigen, e.g., Omp85, to induce an immune
response. The Ab3 antibodies are useful for the same reason the Ab1
are useful. Other uses as research tools and as components for
separation of Omp85 from other contaminants, for example, are also
contemplated for the above-described antibodies.
[0117] For use in diagnostic assays, the antibodies are associated
with conventional labels which are capable, alone or in concert
with other compositions or compounds, of providing a detectable
signal. Where more than one antibody is employed in a diagnostic
method, the labels are desirably interactive to produce a
detectable signal. Most desirably, the label is detectable
visually, e.g. colorimetrically. A variety of enzyme systems have
been described in the art which will operate to reveal a
colorimetric signal in an assay. As one example, glucose oxidase
(which uses glucose as a substrate) releases peroxide as a product.
Peroxidase, which reacts with peroxide and a hydrogen donor such as
tetramethyl benzidine (TMB) produces an oxidized TMB that is seen
as a blue color. Other examples include horseradish peroxidase
(HRP) or alkaline phosphatase (AP), and hexokinase in conjunction
with glucose-6-phosphate dehydrogenase which reacts with ATP,
glucose, and NAD+ to yield, among other products, NADH that is
detected as increased absorbance at 340 nm wavelength. Other label
systems that may be utilized in the methods of this invention are
detectable by other means, e.g., colored latex microparticles
(Bangs Laboratories, Ind.) in which a dye is embedded may be used
in place of enzymes to form conjugates with the antibodies and
provide a visual signal indicative of the presence of the resulting
complex in applicable assays. Still other labels include
fluorescent compounds, radioactive compounds or elements.
Detectable labels for attachment to antibodies useful in diagnostic
assays of this invention may be easily selected from among numerous
compositions known and readily available to one skilled in the art
of diagnostic assays. The methods and antibodies of this invention
are not limited by the particular detectable label or label system
employed.
IV. Diagnostic Methods and Assays
[0118] The present invention also provides methods of diagnosing
infections and diseases caused by infection with N. gonorrhoeae, N.
meningitidis or possibly other species of pathogen which have
homologous proteins to the Omp85 proteins of this invention. These
diagnostic methods are useful for diagnosing humans having
non-symptomatic infection or exhibiting the clinical symptoms of
gonococcal or meningococcal disease, or possibly any of the other
diseases caused by homologous bacterial species.
[0119] In one embodiment, this diagnostic method involves detecting
the presence of naturally occurring anti-Omp85 antibodies which are
produced by the infected human or animal patient's immune system in
its biological fluids, and which are capable of binding to the
antigens of this invention or combinations thereof. This method
comprises the steps of incubating a Omp85 antigen or antigenic
fragment of this invention with a sample of biological fluid or
tissue from the patient. Antibodies present in the fluids as a
result of bacterial infection will form an antibody-antigen complex
with the antigen. Subsequently the reaction mixture is analyzed to
determine the presence or absence of these antigen-antibody
complexes. The step of analyzing the reaction mixture can comprise
detecting a label associated with the Omp85 antigen, or contacting
the reaction mixture with a labeled specific binding partner for
the antibody or antibody.
[0120] In one embodiment of the method, purified antigen, fragment
or mixture of antigens is electro- or dot-blotted onto
nitrocellulose paper. Subsequently, the biological fluid (e.g.
serum or plasma) is incubated with the blotted antigen, and
antibody in the biological fluid is allowed to bind to the
antigen(s). The bound antibody is then detected by standard
immunoenzymatic methods.
[0121] In another embodiment of the method, latex beads are
conjugated to the antigen(s) of this invention. Subsequently, the
biological fluid is incubated with the bead/protein conjugate,
thereby forming a reaction mixture. The reaction mixture is then
analyzed to determine the presence of the antibodies.
[0122] In another embodiment, the diagnostic method of the
invention involves detecting the presence of the naturally
occurring Omp85 itself in its association with the Neisseriae
pathogen in the biological fluids or tissue of an animal or human
infected by the pathogen. This method includes the steps of
incubating an antibody of this invention (e.g. produced by
administering to a suitable human and/or animal an antigen of this
invention preferably conventionally labeled for detection) with a
biological sample from a human or an animal to be diagnosed. In the
presence of infection of the human or animal patient, an
antigen-antibody complex is formed (specific binding occurs).
Subsequently, excess labeled antibody is optionally removed, and
the reaction mixture is analyzed to determine the presence or
absence of the antigen-antibody complex and the amount of label
associated therewith.
[0123] Assays employing a protein antigen of the invention can be
heterogenous (i.e., requiring a separation step) or homogenous. If
the assay is heterogenous, a variety of separation means can be
employed, including centrifugation, filtration, chromatography, or
magnetism.
[0124] One preferred assay for the screening of blood products or
other physiological or biological fluids is an enzyme linked
immunosorbant assay, i.e., an ELISA. Typically in an ELISA, the
isolated antigen(s) of the invention is adsorbed to the surface of
a microtiter well directly or through a capture matrix (i.e.,
antibody). Residual protein-binding sites on the surface are then
blocked with an appropriate agent, such as bovine serum albumin
(BSA), heat-inactivated normal goat serum (NGS), or BLOTTO (a
buffered solution of nonfat dry milk which also contains a
preservative, salts, and an antifoaming agent). The well is then
incubated with a biological sample suspected of containing specific
anti-N. gonorrhoeae or N. meningitidis antibody. The sample can be
applied neat, or more often, it can be diluted, usually in a
buffered solution which contains a small amount (0.1-5.0% by
weight) of protein, such as BSA, NGS, or BLOTTO. After incubating
for a sufficient length of time to allow specific binding to occur,
the well is washed to remove unbound protein and then incubated
with labeled anti-human immunoglobulin (a HuIg) or labeled
antibodies to other species, e.g., dogs. The label can be chosen
from a variety of enzymes, including horseradish peroxidase (HRP),
.beta.-galactosidase, alkaline phosphatase, and glucose oxidase, as
described above. Sufficient time is allowed for specific binding to
occur again, then the well is washed again to remove unbound
conjugate, and the substrate for the enzyme is added. Color is
allowed to develop and the optical density of the contents of the
well is determined visually or instrumentally.
[0125] Further, MAbs or other antibodies of this invention which
are capable of binding to the antigen(s) can be bound to ELISA
plates. In another diagnostic method, the biological fluid is
incubated on the antibody-bound plate and washed. Detection of any
antigen-antibody complex and qualitative measurement of the labeled
MAb are performed conventionally, as described above.
[0126] Other useful assay formats include the filter cup and
dipstick. In the former assay, an antibody of this invention is
fixed to a sintered glass filter to the opening of a small cap. The
biological fluid or sample (5 ml) is worked through the filter. If
the antigen is present (i.e., N. gonorrhoeae infection), it will
bind to the filter which is then visualized through a second
antibody/detector. The dipstick assay involves fixing an antigen or
antibody to a filter, which is then dipped in the biological fluid,
dried and screened with a detector molecule.
[0127] Other diagnostic assays can employ the omp85 gene sequences
or fragments of this invention as nucleic acid probes or an
anti-sense sequences, which can identify the presence of infection
in the biological fluid by hybridizing to complementary sequences
produced by the pathogen in the biological fluids. Such techniques,
such as PCR, Northern or Southern hybridizations etc. are well
known in the art. For this purpose, the nucleic acid sequences or
fragments of this invention may be conventionally labelled by well
known techniques, possibly employing one or more of the labels
described above with reference to use of the antibodies, or with
labels more suited for attachment to nucleic acids. Selection of
such labels is a routine matter and does not limit this
invention.
[0128] It should be understood by one of skill in the art that any
number of conventional protein assay formats, particularly
immunoassay formats, or nucleic acid assay formats, may be designed
to utilize the isolated antigens and antibodies or their nucleic
acid sequences or anti-sense sequences of this invention for the
detection of N. gonorrhoeae or N. meningitidis infection (as well
as infection with other bacteria characterized by antigens
homologous to the Omp85 antigens of this invention) in animals and
humans. This invention is thus not limited by the selection of the
particular assay format, and is believed to encompass assay formats
which are known to those of skill in the art.
V. Diagnostic Kits
[0129] For convenience, reagents for ELISA or other assays
according to this invention may be provided in the form of kits.
Such kits are useful for diagnosing bacterial infection in a human
or an animal sample. Such a diagnostic kit contains an antigen of
this invention and/or at least one antibody capable of binding an
antigen of this invention, or the nucleic acid sequences encoding
such Omp85 antigens or antibodies or their anti-sense sequences.
Alternatively, such kits may contain a simple mixture of such
antigens or nucleic acid sequences, or means for preparing a simple
mixture.
[0130] These kits can include microtiter plates to which the
antigenic proteins or antibodies or nucleic acid sequences of the
invention have been pre-adsorbed, various diluents and buffers,
labeled conjugates for the detection of specifically bound antigens
or antibodies, or nucleic acids and other signal-generating
reagents, such as enzyme substrates, cofactors and chromogens.
Other components of these kits can easily be determined by one of
skill in the art. Such components may include polyclonal or
monoclonal capture antibodies, antigen of this invention, or a
cocktail of two or more of the antibodies, purified or
semi-purified extracts of these antigens as standards, MAb detector
antibodies, an anti-mouse or anti-human antibody with indicator
molecule conjugated thereto, an ELISA plate prepared for
absorption, indicator charts for colorimetric comparisons,
disposable gloves, decontamination instructions, applicator sticks
or containers, and a sample preparator cup. Such kits provide a
convenient, efficient way for a clinical laboratory to diagnose N.
gonorrhoeae or N. meningiditus infection.
VI. Therapeutic and Vaccine Compositions
[0131] A. Protein-Containing Therapeutic and Vaccine
Compositions
[0132] The antigens and antibodies of the invention, alone or in
combination with other antigens and antibodies of, or directed to,
other pathogenic microorganisms may further be used in therapeutic
compositions and in methods for treating humans and/or animals with
non-symptomatic infection or symptomatic disease caused by N.
gonorrhoeae, N. meningitidis or the other pathogens identified
above.
[0133] For example, one such therapeutic composition may be
formulated to contain a carrier or diluent and one or more of the
anti-Omp 85 antibodies of the invention. In compositions containing
the Omp85 antigen or antibodies thereto, i.e., protein components,
suitable pharmaceutically acceptable carriers may be employed that
facilitate administration of the proteins but are physiologically
inert and/or nonharmful.
[0134] A variety of such pharmaceutically acceptable protein
carriers, and/or components suitable for administration therewith
may be selected by one of skill in the art. For example,
pharmaceutical carriers include, without limitation, sterile
saline, lactose, sucrose, calcium phosphate, gelatin, dextran,
agar, pectin, peanut oil, olive oil, sesame oil, and water.
Additionally, the carrier or diluent may include a time delay
material, such as glycerol monostearate or glycerol distearate
alone or with a wax. In addition, slow release polymer formulations
can be used. Liposomes or liposomal-like vehicles may also be
employed.
[0135] Optionally, these compositions may also contain conventional
pharmaceutical ingredients, such as preservatives, or chemical
stabilizers. Suitable ingredients which may be used in a
therapeutic composition in conjunction with the antibodies include,
for example, casamino acids, sucrose, gelatin, phenol red, N-Z
amine, monopotassium diphosphate, lactose, lactalbumin hydrolysate,
and dried milk.
[0136] Alternatively, or in addition to the antigens or antibodies
of the invention, other agents useful in treating the disease in
question, e.g., antibiotics or immunostimulatory agents and
cytokine regulation elements, are expected to be useful in reducing
or eliminating disease symptoms. Such agents may operate in concert
with the therapeutic compositions of this invention. The
development of therapeutic compositions containing these agents is
within the skill of one in the art in view of the teachings of this
invention.
[0137] Additionally, the therapeutic compositions may be
polyvalent. Such compositions may contain therapeutic components
from other bacterial or viral pathogens, e.g., components of
bacterial species homologous to Neiserriae or heterologous thereto
and/or antigens from a disease-causing virus. Depending upon the
compatibility of the components, the Omp 85 antibodies or antigens
of this invention may thus be part of a multi-component therapeutic
composition directed at more than a single disease.
[0138] As a further embodiment of this invention, a therapeutic
method involves treating a human or an animal for infection with N.
gonorrhoeae or N. meningitidis by administering an effective amount
of such a therapeutic composition. An "effective amount" of a
proteinaceous composition may be between about 0.05 to about 1000
.mu.g/ml of an antibody or antigen of the invention. A suitable
dosage may be about 1.0 ml of such an effective amount. Such a
composition may be administered 1-3 times per day over a 1 day to
12 week period.
[0139] However, suitable dosage adjustments for protein or nucleic
acid containing compositions may be made by the attending physician
or veterinarian depending upon the age, sex, weight and general
health of the human or animal patient. Preferably, such a
composition is administered parenterally, preferably
intramuscularly or subcutaneously. However, it may also be
formulated to be administered by any other suitable route,
including orally or topically. The selection of the route of
delivery and dosage of such therapeutic compositions is within the
skill of the art.
[0140] In another embodiment, the Omp85 antigens, antibodies, and
fragments of the invention, alone or in combination with other
antigens, antibodies, and fragments from other microorganisms, may
further be used in compositions directed to induce a protective
immune response in a subject to the pathogen. These components of
the present invention are also useful in methods for inducing a
protective immune response in humans and/or animals against
infection with N. gonorrhoeae, N. meningitidis or the other
pathogens identified above.
[0141] In one embodiment, an outer membrane protein antigen-based
vaccine for the prevention of non-symptomatic gonococcal infection
or symptomatic disease, non-symptomatic meningococcal infection and
symptomatic disease, and other diseases in humans and other animals
is provided which contains an effective amount of the Omp85 antigen
of this invention, and a pharmaceutically acceptable carrier or
diluent. This vaccine composition may contain one or more of the
isolated, recombinant, modified or multimeric forms of the Omp85
antigen of the invention, or mixtures thereof. Similarly, salts of
the antigenic proteins may be employed in such compositions.
[0142] In another embodiment of this invention, a polyvalent
vaccine composition may include not only the Omp85 antigen or
immunogenic fragment thereof, but may also include antigens from
other disease-causing agents. Such other agents may be antigens
from other Neisseriae strains. Such other agents may be antigens
from completely distinct bacterial pathogens or from viral
pathogens. Combinations of the antigen(s) of this invention with
other antigens or fragments thereof are also encompassed by this
invention for the purpose of inducing a protective immune response
in the vaccinated subject to more than a single pathogen. The
selection of these other vaccine components is not a limitation of
the present invention, and may be left to one of skill in the
art.
[0143] Such proteinaceous vaccines may include exemplary carriers
as described above for therapeutic compositions. Optionally, the
vaccine compositions may optionally contain adjuvants,
preservatives, chemical stabilizers, as well as other
conventionally employed vaccine additives. Typically, stabilizers,
adjuvants, and preservatives are optimized to determine the best
formulation for efficacy in the target human or animal. Suitable
exemplary preservatives include chlorobutanol, potassium sorbate,
sorbic acid, sulfur dioxide, propyl gallate, the parabens, ethyl
vanillin, glycerin, phenol, and parachlorophenol.
[0144] With regard to the adjuvant, one or more of the above
described vaccine components may be admixed or adsorbed with a
conventional adjuvant. The adjuvant is used to attract leukocytes
or enhance an immune response. Such adjuvants include, among
others, RIBI adjuvant, mineral oil and water, aluminum hydroxide,
AMPHIGEN adjuvant, ADJUVAX adjuvant, AVRIDINE adjuvant,
L121/squalene, D-lactide-polylactide/glycoside, pluronic plyois,
muramyl dipeptide, killed Bordetella, and saponins, such as Quil
A.
[0145] The invention thus also encompasses a prophylactic method
entailing administering to an animal or human an effective amount
of such a composition. The protein antigenic composition is
administered in an "effective amount", that is, an amount of
antigen that is effective in a route of administration to provide a
vaccinal benefit, i.e., protective immunity. Suitable amounts of
the antigen can be determined by one of skill in the art based upon
the level of immune response desired. In general, however, the
vaccine composition contains between 1 ng to 1000 mg antigen, and
more preferably, 0.05 .mu.g to 1 mg per ml of antigen. Suitable
doses of the vaccine composition of the invention can be readily
determined by one of skill in the art. Generally, a suitable dose
is between 0.1 to 5 ml of the vaccine composition. Further,
depending upon the human patient or the animal species being
treated, i.e. its weight, age, and general health, the dosage can
also be determined readily by one of skill in the art.
[0146] In general, the vaccine can be administered once; and
optionally boosters can be administered periodically thereafter.
The vaccine may be administered by any suitable route. However,
parenteral administration, particularly intramuscular, and
subcutaneous, is the preferred route. Also preferred is the oral
route of administration. Routes of administration may be combined,
if desired, or adjusted.
[0147] In still another vaccine embodiment, the invention includes
a composition which delivers passive protection against infection
by the pathogen. For this composition, the antibodies against the
Omp85 proteins disclosed herein are useful to provide to the
subject a short-term, passive immune protection against infection.
These passive immunity vaccine compositions may contain antibodies
to other pathogens and suitable vaccine additives as described
above, e.g., adjuvants, etc. These compositions may be administered
in dosages similar to those described above for the compositions
which actively induce immune protection in the vaccinated
subject.
[0148] B. Nucleic Acid Containing Compositions
[0149] The nucleic acid sequences or anti-sense sequences of the
invention, alone or in combination with other nucleic acid
sequences encoding antigens or antibodies of, or directed to other
pathogenic microorganisms may further be used in therapeutic
compositions and in methods for treating humans and/or animals with
the disease caused by infection with N. gonorrhoeae, N.
meningitidis or the other pathogens identified above. In another
embodiment, the nucleic acid sequences of this invention, alone or
in combination with nucleic acid sequences encoding other antigens
or antibodies from other pathogenic microorganisms, may further be
used in compositions directed to actively induce a protective
immune response in a subject to the pathogen. These components of
the present invention are useful in methods for inducing a
protective immune response in humans and/or animals against
infection with N. gonorrhoeae, N. meningitidis or the other
pathogens identified above.
[0150] For use in the preparation of the therapeutic or vaccine
compositions, nucleic acid delivery compositions and methods are
useful, which are known to those of skill in the art. The omp85
sequences or fragments thereof (or anti-sense sequences as desired)
may be employed in the methods of this invention or in the
compositions described herein as DNA sequences, either administered
as naked DNA, or associated with a pharmaceutically acceptable
carrier. These sequences provide for in vivo expression of the
Omp85 protein or peptide or provide for production of anti-sense
sequences which can bind to the Omp85 protein in the subject due to
infection. So-called `naked DNA` may be used to express the Omp85
protein or peptide fragment (or anti-sense sequences) in vivo in a
patient. See, e.g., J. Cohen, Science, 259:1691-1692 (Mar. 19,
1993); E. Fynan et al., Proc. Natl. Acad. Sci., USA, 90:
11478-11482 (December 1993); J. A. Wolff et al., Biotechniques,
11:474-485 (1991) which describe similar uses of `naked DNA`, all
incorporated by reference herein. For example, "naked" omp85 DNA
(or anti-sense sequences) associated with regulatory sequences may
be administered therapeutically or as part of the vaccine
composition e.g., by injection.
[0151] Alternatively, omp85 DNA or anti-sense DNA may be
administered as part of a vector or as a cassette containing the
Omp85-encoding DNA sequences or fragments or anti-sense sequences
thereof operatively linked to a promoter sequence and other plasmid
sequences. Briefly, the DNA encoding the Omp85 protein (or
anti-sense sequence) or desired fragment thereof may be inserted
into a nucleic acid cassette. This cassette may be engineered to
contain, in addition to the omp85 sequence to be expressed (or
anti-sense sequence), other optional flanking sequences which
enable its insertion into a vector. This cassette may then be
inserted into an appropriate DNA vector downstream of a promoter,
an mRNA leader sequence, an initiation site and other regulatory
sequences capable of directing the replication and expression of
that sequence in vivo. This vector permits infection of vaccinate's
cells and expression of the omp85 (or anti-sense sequence) in
vivo.
[0152] Numerous types of appropriate vectors are known in the art
for protein expression and may be designed by standard molecular
biology techniques. Such vectors are selected from among
conventional vector types including insects, e.g., baculovirus
expression, or yeast, fungal, bacterial or viral expression
systems. Methods for obtaining such vectors are well-known. See,
Sambrook et al., Molecular Cloning. A Laboratory Manual, 2d
edition, Cold Spring Harbor Laboratory, New York (1989); Miller et
al., Genetic Engineering, 8:277-298 (Plenum Press 1986) and
references cited therein. Recombinant viral vectors, such as
retroviruses or adenoviruses, are preferred for integrating the
exogenous DNA into the chromosome of the cell.
[0153] Also where desired, the regulatory sequences in such a
vector which control and direct expression of the omp85 gene
product or anti-sense sequence in the transfected cell include an
inducible promoter. Inducible promoters are those which "turn on"
expression of the gene when in the presence of an inducing agent.
Examples of suitable inducible promoters include, without
limitation, the sheep metallothionine (MT) promoter, the mouse
mammary tumor virus (MMTV), the tet promoter, etc. The inducing
agents may be a glucocorticoid such as dexamethasone, for, e.g.,
the MMTV promoter, or a metal, e.g., zinc, for the MT promoter; or
an antibiotic, such as tetracycline for tet promoter. Still other
inducible promoters may be selected by one of skill in the art,
such as those identified in International patent application
WO95/13392, published May 18, 1995, and incorporated by reference
herein. The identity of the inducible promoter is not a limitation
of this invention.
[0154] When omp85 nucleic acid sequences or anti-sense sequences
are employed as the therapeutic agent or vaccine agent as `naked
DNA` operatively linked to a selected promoter sequence, rather
than the protein itself, the amounts of DNA to be delivered and the
routes of delivery may parallel the protein amounts for vaccine or
therapeutic delivery described above and may also be determined
readily by one of skill in the art.
[0155] Thus, as one preferred example, a therapeutic composition
may be formulated to contain a carrier or diluent and one or more
plasmid or DNA molecule or recombinant virus containing a nucleic
acid sequence which is anti-sense to the omp85 gene sequence (SEQ
ID NO: 1 or 3), a fragment thereof, under control of suitable
sequences regulating the expression thereof. In compositions
containing the anti-sense omp85 nucleic acid sequences, vehicles
suitable for delivery of DNA may be employed.
[0156] Additionally, these therapeutic compositions may be
polyvalent. Such compositions may contain therapeutic components
which are anti-sense sequences of other bacterial or viral origin,
e.g., the anti-sense sequence of components of bacterial species
homologous to Neiserriae or heterologous thereto and/or anti-sense
sequence derived from antigens from a disease-causing virus.
Depending upon the compatibility of the components, the anti-sense
sequences to the Omp85 antigens of this invention may thus be part
of a multi-component therapeutic composition directed at more than
a single disease.
[0157] As a further embodiment of this invention, a therapeutic
method involves treating a human or an animal for infection with N.
gonorrhoeae or N. meningitidis by administering an effective amount
of such a therapeutic nucleic-acid containing composition. An
"effective amount" of a nucleic acid composition may be calculated
as that amount capable of expressing in vivo the above effective
amounts of exogenously delivered proteins. Such amounts may be
determined by one of skill in the art. Preferably, such a
composition is administered parenterally, preferably
intramuscularly or subcutaneously. However, it may also be
formulated to be administered by any other suitable route,
including orally or topically. The selection of the route of
delivery and dosage of such therapeutic compositions is within the
skill of the art.
[0158] As another example, a vaccine composition of this invention
may be a DNA vaccine, which includes the omp85 DNA sequence (SEQ ID
NOS: 1 or 3) or a fragment thereof which encodes an immunogenic
protein or peptide, optionally under the control of regulatory
sequences. In one embodiment, this vaccine composition may contain
a nucleic acid sequence that encodes one or more of the isolated,
recombinant, modified or multimeric forms of the Omp85 antigen of
the invention, or mixtures thereof.
[0159] In another embodiment of this invention, polyvalent vaccine
compositions may include not only the nucleic acid sequence
encoding the Omp85 antigen or an immunogenic fragment thereof, but
may also include nucleic acid sequences encoding antigens from
other disease-causing agents. Such other agents may be antigens
from other Neisseriae strains. Such other agents may be nucleic
acid sequences encoding antigens from completely distinct bacterial
pathogens or from viral pathogens. Combinations of the
antigen-encoding sequences of this invention with other nucleic
acid sequences encoding antigens or fragments thereof from other
pathogens are also encompassed by this invention for the purpose of
inducing a protective immune response in the vaccinated subject to
more than a single pathogen. The selection of these other vaccine
components is not a limitation of the present invention, and may be
left to one of skill in the art.
[0160] Such "DNA" or nucleic acid vaccines may include exemplary
carriers as described above for therapeutic compositions and, where
suitable, the components or additives described above with
reference to the proteinaceous compositions, e.g. adjuvants,
preservatives, chemical stabilizers, etc. as well as other
conventionally employed vaccine additives. Additives suitable for
use in nucleic acid compositions are known to those of skill in the
art, including certain lipids and liposomes, among other known
components.
[0161] Generally, a suitable nucleic acid-based treatment contains
between 1.times.10.sup.-3 plaque forming unit (pfu) to
1.times.10.sup.12 pfu per dose, if a virus is the delivery vector.
Otherwise, the dosage is adjusted to provide the same amount of
expressed protein as is provided by the protein vaccines. However,
the dose, timing and mode of administration of these compositions
may be determined by one of skill in the art. Such factors as the
age, and physical condition of the vaccinate may be taken into
account in determining the dose, timing and mode of administration
of the immunogenic or vaccine composition of the invention.
VII. Drug Screening and Development
[0162] The proteins, antibodies and polynucleotide sequences of the
present invention may also be used in the screening and development
of chemical compounds or proteins which have utility as therapeutic
drugs or vaccines for the treatment or diagnosis or prevention of
diseases caused by infection with N. gonorrhoeae or N.
meningitidis, and possibly for the other microorganisms having
homologous proteins to Omp85. As one example, a compound capable of
binding to Omp85 and preventing its biological activity may be a
useful drug component for the treatment or prevention of such
non-symptomatic gonococcal infection or symptomatic diseases as
gonorrhea and non-symptomatic meningococcal infection and
symptomatic disease, e.g., spinal meningitis, among others. The
methods described herein may also be applied to fragments of
Omp85.
[0163] Suitable assay methods may be readily determined by one of
skill in the art. Where desired, and depending on the assay
selected, the selected antigen(s), e.g., Omp85 or fragment thereof,
may be immobilized directly or indirectly (e.g., via an Omp85
antibody) on a suitable surface, e.g., in an ELISA format. Such
immobilization surfaces are well known. For example, a wettable
inert bead may be used. Alternatively, the selected antigen, e.g.,
Omp85, may be used in screening assays which do not require
immobilization, e.g., in the screening of combinatorial libraries.
Assays and techniques exist for the screening and development of
drugs capable of binding to an antigen of this invention, e.g.,
Omp85. These include the use of phage display system for expressing
the antigenic protein(s), and using a culture of transfected E.
coli or other microorganism to produce the proteins for binding
studies of potential binding compounds. See, for example, the
techniques described in G. Cesarini, FEBS Letters, 307(1):66-70
(July 1992); H. Gram et al., J. Immunol. Meth., 161:169-176 (1993);
C. Summer et al., Proc. Natl. Acad. Sci., USA, 89:3756-3760 (May
1992), incorporated by reference herein.
[0164] Other conventional drug screening techniques may be employed
using the proteins, antibodies or polynucleotide sequences of this
invention. As one example, a method for identifying compounds which
specifically bind to a protein of this invention, e.g., Omp85, can
include simply the steps of contacting a selected Omp85 protein
with a test compound to permit binding of the test compound to
Omp85; and determining the amount of test compound, if any, which
is bound to the Omp85 protein. Such a method may involve the
incubation of the test compound and the Omp85 protein immobilized
on a solid support. Similar methods may be employed for one or more
of the cassette string proteins.
[0165] Typically, the surface containing the immobilized ligand is
permitted to come into contact with a solution containing the
protein and binding is measured using an appropriate detection
system. Suitable detection systems include the streptavidin horse
radish peroxidase conjugate, direct conjugation by a tag, e.g.,
fluorescein. Other systems are well known to those of skill in the
art. This invention is not limited by the detection system
used.
[0166] Another method of identifying compounds which specifically
bind to Omp85 or another protein of this invention can include the
steps of contacting the protein, e.g., Omp85, immobilized on a
solid support with both a test compound and the protein sequence
which is a receptor for Omp85 to permit binding of the receptor to
the Omp85 protein; and determining the amount of the receptor which
is bound to the Omp85 protein. The inhibition of binding of the
normal protein by the test compound thereby indicates binding of
the test compound to the Omp85 protein.
[0167] Still other conventional methods of drug screening can
involve employing a suitable computer program to determine
compounds having similar or complementary chemical structures to
that of the Omp85 proteins (SEQ ID NOS: 2 and 4), and screening
those compounds for competitive binding to Omp85. Such programs
include the GRID program available from Oxford University, Oxford,
UK. (P. J. Goodford, "A Computational Procedure for Determining
Energetically Favorable Binding Sites on Biologically Important
Macromolecules", J. Med. Chem., 28:849-857 (1985)); the MCSS
program available from Molecular Simulations, Burlington, Mass. (A.
Miranker and M. Karplus, "Functionality Maps of Binding Sites: A
Multiple Copy Simultaneous Search Method", Proteins: Structure,
Function and Genetics, 11:29-34 (1991)); the AUTODOCK program
available from Scripps Research Institute, La Jolla, Calif. (D. S.
Goodsell and A. J. Olsen, "Automated Docking of Substrates to
Proteins by Simulated Annealing", Proteins: Structure, Function,
and Genetics, 8:195-202 (1990)); and the DOCK program available
from University of California, San Francisco, Calif. (I. D. Kuntz
et al., "A Geometric Approach to Macromolecule-Ligand
Interactions", J. Mol. Biol., 161:269-288 (1982)). Additional
commercially available computer databases for small molecular
compounds include Cambridge Structural Database, Fine Chemical
Database, and CONCORD database. For a review see Rusinko, A., Chem.
Des. Auto. News, 8:44-47 (1993).
[0168] Thus, the invention provides a method of identifying a
pharmacomimetic of Omp85 of N. gonorrhoeae or N. meningitidis by
using a combination of steps including identifying a compound which
binds to Omp85 by screening said Omp85 against a battery of
compounds. Computer modelling of the three dimensional structure of
Omp85 or of the previously identified binding compound permits the
identification of a compound with the same three dimensional
structure as either Omp85 or its binding compound. The compound
selected from these tests is then screened for the biological
activity of Omp85 or of a compound that binds Omp85, such as the
development of antisera effective in the assay of Example 8 or
competitive effect in that assay, respectively.
[0169] Thus, through use of such methods, the present invention is
anticipated to provide compounds capable of interacting with Omp85
or portions thereof, and either enhancing or decreasing its
biological activity, as desired. Such compounds are believed to be
encompassed by this invention.
[0170] The following examples are provided to illustrate the
invention and do not limit the scope thereof. One skilled in the
art will appreciate that although specific reagents and conditions
are outlined in the following examples, modifications can be made
which are meant to be encompassed by the spirit and scope of the
invention.
Example 1
Bacterial Strains, Cells, Methods and Culture Conditions
[0171] N. gonorrhoeae strains FA19, FA635, FA1090, JS1, F62 and
MS11LosA used in the examples below were provided by Dr. William M.
Shafer (Emory University, Atlanta, Ga.) Dr. John Swanson (Rocky
Mountain Laboratories, Hamilton, Mont.) or the American Type
Culture Collection 10801 University Boulevard, Manassas, Va.
20110-2209. N. meningitidis strains MP78, MP3, MP81, and HH were
provided by Dr. Mark S. Peppler (University of Alberta, Edmonton,
Alberta, Canada) and Dr. Zell McGee (University of Utah, Salt Lake
City, Utah). All other strains were acquired from the American Type
Culture Collection. Moraxella catarrhalis (ATCC# 8193) and
Neisserial strains were grown on clear gonococcal typing media
(Swanson J., Infect. Immun., 19: 320-331 (1978)). E. coli and all
other Gram negative strains were grown an Luria broth.
[0172] E. coli XL1-Blue and SOLR cells were obtained from
Stratagene Cloning Systems (La Jolla, Calif.). DNA fragments were
purified from agarose gels using GENE CLEAN.TM. II (Bio101, La
Jolla, Calif.). Plasmids were purified using the QIAPREP.TM. quick
spin kit (Qiagen, Chatsworth, Calif.) Immunoblotting was done with
MILLIPORE IMMOBILON.TM. PVDF reagent (Bedford, Mass.). Unless
specified otherwise in the examples below, all reagents were
obtained from Sigma Chemical Co. (St. Louis, Mo.).
Example 2
Cloning and Immunological Screening of a Gonococcal Genomic
Library
[0173] A genomic DNA library was produced by purifying N.
gonorrhoeae strain FA19 genomic DNA and partially digesting the DNA
into fragments with the restriction endonuclease Tsp509 (New
England Biolabs). These DNA fragments were ligated with T4 DNA
ligase (New England Biolabs) into the EcoRI restriction site of the
lambda ZAP II.TM. bacteriophage vector (Stratagene Cloning Systems,
La Jolla, Calif.). The ligated phage DNA was packaged, and plated
on E. coli DH5a (Gibco BRL, Gaithersburg, Md.) host cells. The
resulting library was screened immunologically for the expression
of gonococcal surface proteins according to protocols provided with
the Lambda ZAP II.TM. vector system. The plaques from the library
were screened with anti-GC-OM, an antiserum raised to isolated
gonococcal outer membranes.
[0174] Plasmid DNA was rescued from phage producing immunoreactive
plaques. The plasmid, pDR4, contained a 2.6 kbp gonococcal DNA
insert. The gonococcal DNA in pDR4 was subcloned into pUP1 (Elkins
C., J. Bacteriol., 173: 3911-3913 (1991), generously provided by
Dr. Chris Elkins (University of North Carolina, Chapel Hill, N.C.)
yielding pOmp85.
[0175] The cloned gonococcal DNA fragment in pOmp85 was
characterized by restriction enzyme analysis. The fragment
contained three internal HincII restriction sites which allowed the
subcloning of three fragments into PBluescript.TM. plasmid
(Stratagene Cloning Systems, La Jolla, Calif.). These fragments and
pDR4 were sequenced by the University of Montana Molecular Biology
Facility. A gene-walking strategy was used to sequence those
regions which could not be sequenced with universal vector primers.
The entire length of the gonococcal DNA fragment was sequenced at
least twice and most of the DNA was sequenced from both strands.
The deduced amino acid sequence and comparisons of Omp85 homologs
were obtained with the MACVECTOR.TM. software package (Eastman
Chemical Co., New Haven, Conn.).
[0176] The 2.6 kb gonococcal DNA in pOmp85 was found to contain a
large open reading frame (ORF) which encoded a polypeptide of 792
amino acids with a predicted molecular weight of 87.8 kDa (FIGS.
2A-2C) (SEQ ID NO:2). The polypeptide contained a putative signal
peptide (Von Heijne G., Nuc. Acids Res., 14: 4683-4690 (1986)).
Removal of this signal peptide yielded a mature polypeptide with an
85.8 kDa predicted molecular weight. The polypeptide also possesses
a carboxyl-terminal phenylalanine residue characteristic of outer
membrane proteins (Struyve M. et al., J. Mol. Biol., 218: 141-148
(1991)). A ribosome-binding sequence preceded the initiation codon
of the ORF. Potential promoter sequences were not readily apparent.
The ORF was preceded and followed by putative rho-independent
transcriptional stop sites. The approximately 85 kDa gonococcal
protein expressed by pOmp85 was designated Omp85 and the gene
encoding it was designated omp85.
Example 3
Cloning and Sequencing of Meningococcal OMP85
[0177] The meningococcal omp85 was obtained by PCR amplification
using the Boehringer Mannheim EXPAND HIGH FIDELITY.TM. PCR System
(Indianapolis, Ind.). The design of PCR primers was based on
gonococcal omp85 and flanking sequences. The positive-sense omp85
PCR primer contained the first five codons of the gonococcal omp85
with an EcoRI restriction site and two extra nucleotides added to
the 5' end (CGGAATTCATGAAACTGAAACAG) (SEQ ID NO: 5). The
negative-sense omp85 PCR primer contained the reverse-compliment of
six codons (TTGCAGTTTTTGCAATTC) (SEQ ID NO: 6) of the gonococcal
ompH sequence located 244 base pairs 3' of omp85 termination codon.
These primers were used in a PCR reaction with purified N.
meningitidis HH DNA as template. The meningococcal omp85 PCR
product was ligated into pUP1 to yield pMCOmp85. The sequence of
the meningococcal omp85 was obtained essentially as described for
the gonococcal omp85.
[0178] The meningococcal omp85 was found to encode a 797 amino acid
polypeptide with a predicted molecular weight of 88.5 kDa (FIG. 5).
The meningococcal omp85 was 95% identical and 98% similar to
gonococcal omp85. Between amino acid residues 720 and 745, the
menigococcal Omp85 varied substantially from gonococcal Omp 85,
including the insertion of five additional amino acids.
Example 4
Presence of OMP85 in Strains of N. Gonorrhoeae and N.
Meningitidis
[0179] A. Western Analysis
[0180] The Western blot analyses were performed as follows.
Bacterial proteins were separated by SDS-PAGE (12.5%) (Laemmli U K,
Nature, 227: 680-695 (1970)). The separated proteins were
electrophoretically transferred onto PVDF as previously described
(Judd R C., Anal. Biochem., 173: 307-316 (1988)). Blotting was
performed in 20 mM sodium phosphate buffer, pH 8.0 for 2 hr at 600
mA. The PVDF membrane was blocked for 1 hr with PBS Tween at room
temperature, incubated overnight in anti-GC-OM or anti-Omp85 sera
at 4.degree. C., washed several times, incubated with protein
A-horseradish peroxidase conjugate (Boehringer Mannheim,
Indianapolis, Ind.) and developed with 4-chloro-1-naphthol.
[0181] Western blot analysis of the proteins from E. coli
DH5a/pOmp85 was performed by separating bacterial cell lysates by
SDS-PAGE, staining with COOMASSIE BRILLIANT BLUE.TM. (CBB) stain or
transferring the lysates to membranes and probing with anti-GC-OM
serum. The results revealed expression of an approximately 85 kDa
polypeptide that was reactive with the anti-GC-OM serum (FIG.
1).
[0182] Anti-GC-OM serum was reacted in Western blot analysis with
total cell proteins from six representative strains of N.
gonorrhoeae and four strains of N. meningitidis. Whole cell lysates
of E. coli DH5a, E. coli DH5a/pOmp85, and N. gonorrhoeae strains
FA19, FA635, FA1090, JS1, F62 and MS11LosA and N. meningitidis
strains MP78, MP3, MP81 and HH were separated by 12.5% SDS-PAGE,
blotted and probed with the anti-GC-OM serum. An immunoreactive,
approximately 85 kDa protein band was detected in all strains of N.
gonorrhoeae and N. meningitidis (FIG. 3), but not in the control E.
coli DH5a.
[0183] B. Southern Analysis
[0184] The Southern analyses are performed as follows. Chromosomal
DNA was obtained by phenol extraction (Moore D., "Preparation and
analysis of DNA", in: Ausubel F M, et al., eds. Current Protocols
in Molecular Biology. New York: John Wiley and Sons, (1997):
2.1.1-2.1.3) and then digested with various endonucleases. Digested
DNA was electrophoretically separated on a 1% agarose gel and the
DNA transferred to nitrocellulose with the BIO-RAD.TM. Model 785
vacuum blotter according to instructions and Southern (Southern E.,
J. Mol. Biol., 98: 503-510 (1975)). Probe DNA was extracted from
agarose gels using Bio 101 glassmilk (Vista, Calif.). The probe was
labeled and the blot probed with the AMERSHAM ECL.TM. system
(Arlington Heights, Ill.).
[0185] A Southern blot (FIG. 4) illustrated the identification of
omp85 in N. gonorrhoeae and N. meningitidis by Southern analysis.
Genomic DNA from E. coli DH5a, N. gonorrhoeae FA19 and N.
meningitidis strains MP3, MP73, MP81 and HH were digested with
restriction endonucleases (HincII, EcoRI, PstI, ClaI). Blots of the
separated DNA digests were probed with a 688 by fragment of
gonococcal omp85 that extended from the most 3' HincII site of
omp85 to a HincII site in the vector near the 3' end of the cloned
gene. This fragment was used as a positive control.
[0186] In N. gonorrhoeae strain FA19 and in all of the N.
meningitidis strains, the omp85 probe hybridized with a single DNA
band. A single band was also identified in gonococcal strains
FA635, FA1090, JS1, F62, and MS11 (data not shown). These results
suggested that omp85 was conserved as a single copy in pathogenic
Neisseria. Sequence data indicated that HincII cleaved omp85
internally at three sites. The probe hybridized to a fragment
larger than itself in the HincII digest of gonococcal DNA
(FA19-HincII). The genomic fragment resulted from an internal and
external HincII cleavage; the probe lacked the flanking gonococcal
sequence containing the external HincII site. The genomic HincII
band that hybridized to the probe was probably derived from a
single copy of the omp85 gene since it is unlikely that duplicate
copies of the gene would have identically-located HincII sites,
generating fragments of identical size.
[0187] The enzyme PstI cleaved 309 base pairs from the 5' end of
omp85. The single fragment of PstI-digested gonococcal genomic DNA
(FA19-PstI) which hybridized with the probe probably contained a
single copy of the gene. It is possible, but unlikely, that the
PstI fragments contained approximately 2 kbp segments of omp85 in
inverted orientations at each end of the approximately 8 kbp
fragment. Sequence data indicated that the enzymes ClaI and EcoRI
did not cleave within omp85. The omp85 probe hybridized to single
bands of similar size in the ClaI digested DNA of both N.
gonorrhoeae and N. meningitidis. These bands suggested a single
copy of omp85, since it is unlikely that bands this small (<6
kbp) contained two copies of the approximately 2.3 kbp gene and it
is unlikely that the bands represent fragments of identical size
from duplicate copies of the gene. Similar results were obtained
for gonococcal strains FA635, FA1090, JS1, F62 and MS11 (data not
shown). These results support the conclusion that omp85 is
conserved as a single copy in pathogenic Neisseria.
Example 5
Similarity to Known Proteins
[0188] The non-redundant Genbank CDS database was searched (Altchul
S D. et al., J. Mol. Biol., 215: 403-407 (1990)) for proteins
similar to gonococcal Omp85. The H. influenzae D-15-Ag was 31.5%
identical and 61.4% similar (identical plus conserved) to
gonococcal Omp85. The P. multocida Oma87 was 31.6% identical and
61.3% similar to Omp85. Several hypothetical proteins with
similarity to Omp85 were identified. A Brucella abortus
hypothetical protein (Genbank accession #U51683, Bearden, et al.,
unpublished) was 24.3% identical and 54.2% similar. A hypothetical
E. coli protein (Genbank accession #U70214, Schramm, et al.,
unpublished) was 33% identical and 62% similar to Omp85. The
gonococcal Omp85 was also similar to hypothetical proteins of
Helicobacter pylori (Genbank assession # AE001178--Tomb J F. et
al., Nature, 388: 539-547 (1997)), 23% identical and 51% similar,
and Borrelia burgdorferi (Genbank assession #AE001178--Fraser C M.
et al., Nature, 390: 580-586 (1997)), 18% identical and 46%
similar.
Example 6
Gene Organization and Flanking Genes
[0189] Several hundred base pairs of the DNA flanking the omp85
ORFs of both N. gonorrhoeae and N. meningitidis were sequenced. For
both N. gonorrhoeae and N. meningitidis, a gene similar to ompH of
Salmonella typhimurium (Kosk P. et al., J. Biol. Chem.,
264:18973-18980 (1989)) was identified approximately 65 base pairs
3' of the omp85 ORF. A gene similar to ompH has also been
identified in the same relative position in H. influenzae
(Fleischmann, R D et al., Science, 269: 496-512 (1995)) and P.
multocida. In H. influenzae, a gene encoding a hypothetical
protein, HI0918, was located 5' of the D-15-Ag gene (Fleischmann, R
D et al, Science, 269: 496-512 (1995)). A gene homologous to the
HI0918 gene was identified at the same relative position in N.
gonorrhoeae. These results indicated that the gene arrangement
around omp85 homologs was notably conserved.
Example 7
Presence In Neisseriae and Other Species
[0190] Western blot analysis was used to determine if proteins
similar to Omp85 were produced by commensal Neisseriae and by other
Gram negative species. To allow more specific immunological
analysis, an Omp85-specific polyvalent rabbit sera was produced
through use of a fusion protein in which the first 200 amino acids
of the gonococcal Omp85 were genetically fused to maltose binding
protein (MBP).
[0191] A. Production of a MBP/Omp85 Fusion Protein
[0192] Fragments of gonococcal Omp85 were genetically fused to MBP,
affinity purified and used to produce Omp85-specific antiserum.
Tsp5091 digested omp85 from pOmp85 was ligated into the EcoRI
digested, maltose binding protein fusion vector, pMAL-c2 (New
England Biolabs, Beverly, Mass.). Sequence analysis had revealed
that this could result in the fusion of several different omp85
fragments in frame with malE in pMAL-c2. The ligated DNA was
transformed into E. coli DH5a and the transformants were screened
for the expression of Omp85 antigens with the anti-OM serum. A
number of immunoreactive clones were identified and characterized.
The plasmid in the most immunoreactive of these was designated pMO4
and determined by sequence analysis to express a fusion of MBP with
the first 181 amino acids of Omp85. The MBP/Omp85 fusion protein
was affinity purified from E. coli DH5a/pMO4 as previously
described (Marchion D C et al, Mol. Microbiol., 6: 231-240
(1997)).
[0193] B. Raising of Anti-Sera
[0194] Purified MBP/Omp85 was used to raise an anti-Omp85 sera in
New Zealand white rabbits. The rabbits were initially immunized
with 1 mg of protein in Freund's complete adjuvant administered
subcutaneously. Two weeks later 1 mg was administered
subcutaneously in Freund's incomplete adjuvant. The rabbits then
received intravenous injections of 0.1 mg every two weeks for eight
weeks. Sera was collected and absorbed (1:1) with a lysed culture
of E. coli/pMal-c2 induced with 1 mM IPTG for 1 hour. The resulting
rabbit serum was designated anti-Omp85.
[0195] C. Western Analysis of Representative Strains of N.
gonorrhoeae and N. Meningitidis
[0196] The anti-Omp85 serum was used to probe Western blots
containing cell lysates of E. coli DH5a, E. coli DH5a/pOmp85 and
representative strains of N. gonorrhoeae and N. meningitidis (FIG.
6). Whole cell lysates of E. coli DH5a, E. coli DH5a/pOmp85, N.
gonorrhoeae strains FA19, FA635, FA1090, JS1, F62 and MS11LosA, N.
meningitidis strains MP78, MP3, MP81 and HH, and E. coli
DH5a/pMCOmp85 were separated by 12.5% SDS-PAGE, blotted and probed
with the anti-Omp85 serum.
[0197] The anti-Omp85 serum reacted with the recombinant Omp85
produced by E. coli DH5a/pOmp85 and with proteins of approximately
85 kDa in all of the N. gonorrhoeae and N. meningitidis strains
tested. These results indicated that Omp85 was conserved in the
pathogenic Neisseriae. Presorption of the antiserum removed the
majority of non-specific antibodies, but complete removal of all
reactive antibody is not possible, thus, some reactive bands can be
seen in the E. coli lanes of FIG. 6. Reactive bands in the 35
kDa-42 kDa range in N. gonorrhoeae lanes are Por proteins, which
non-specifically bind protein-A. Meningococcal Pors do not bind
protein-A as strongly (data not shown).
[0198] D. Western Analysis of Commensal Nesseriae and Other Gram
Negative Species
[0199] The anti-Omp85 was also used to probe Western blots
containing cell lysates of commensal Nesseriae and several other
Gram negative species. Whole cell lysates of E. coli DH5a, E. coli
DH5a/pOmp85, N. gonorrhoeae FA19 (A), Neisseria pharyngis (A),
Neisseria cinerea (A), Neisseria lactamica (B), Neisseria mucosae
(B), Neisseria flavescens (C), Neisseria animalis (C), Neisseria
denitrificans (C), Moraxella catarrhalis (D), Klebsiella
pneumoniae, Pseudomonas aeruginosa, and N. meningitidis HH (A) were
separated in a 12.5% SDSaPAGE gel, blotted and probed with
anti-Omp85. In a separate experiment, whole cell lysates of E. coli
DH5a, E. coli DH5a/pOmp85, N. gonorrhoeae FA19, Salmonella
typhimurium, Shigella flexneri, E. coli strains 35150
(enterohemorrhagic--EHEC), 35401 (enterotoxigenic--ETEC), 43887
(enteropathogenic--EPEC), 43892 (enteroinvasive--EIEC) and N.
meningitidis were separated in a 12.5% SDS-PAGE gel, blotted and
probed with anti-Omp85.
[0200] Two SDS-PAGE (FIGS. 7A and 7B) illustrate the distribution
of Omp85 in pathogenic and commensal Neisseria (relationship areas
A, B, C, and D) and related Gram negative bacteria. Omp85 homologs
were identified in all of the commensal Neisserial species tested.
This suggested that Omp85 was conserved among all the Neisserial
species. The anti-Omp85 serum failed to identify any Omp85 homologs
in Moraxella catarrhalis which is closely related to the Neisseriae
(Rossau R. et al, Int. J. Syst. Bacteriol., 39: 185-198 (1989)).
Southern analysis confirmed the absence of an omp85 homolog in this
species (data not shown). The serum failed to identify any Omp85
homologs in Klebsiella pneumoniae, Pseudomonas aeruginosa,
Salmonella typhimurium, Shigella flexneri and four pathogenic
strains of E. coli tested.
Example 8
Gonococcal Cell Adherence Assay
[0201] Gonococcal cell adherence assays were performed to evaluate
the effect of antiserum specific for outer membrane protein 85
(Omp85) on the ability of gonococcal strains MS11LOSA (MS11) and
FA19 to bind to Chang epithelial cells. Fab fragments were prepared
from antiserum to the first 178 amino acids of Omp85 (SEQ ID NO:
2), hyperimmune antiserum to bovine serum albumin (BSA) and normal
rabbit serum (NRS) and added at 1 .mu.g, 10 .mu.gs or 100 .mu.gs
per ml to wells containing a confluent layer of Chang conjunctiva
cells. Approximately 2.5.times.10.sup.5 bacteria (N. gonorrhoeae
strain MS11 or FA19) were added to each well and allowed to adhere
for 3 hours. Following fixation and immunogold/silver staining, the
number of adherent gonococci was determined for 22 cells. The
lowest and highest numbers were discarded and the average number of
bacteria/cell were determined. The resulting data is reported in
the bar graph of FIG. 8, indicating that Omp85-specific antibody
was able to bind to the surface of the bacteria and interfere with
the ability of the bacteria to adhere to the Chang epithelial
cells.
[0202] All publications cited in this specification are indicative
of the level of skill of those in the art to which this application
pertains and are incorporated herein by reference herein. While the
invention has been described with reference to a particularly
preferred embodiment, it will be appreciated that modifications can
be made without departing from the spirit of the invention. Such
modifications are intended to fall within the scope of the appended
claims.
Sequence CWU 1
1
812379DNANeisseria gonorrhoeaeCDS(1)..(2376) 1atg aaa ctg aaa cag
att gcc tcc gca ctg atg atg ttg ggc ata tcg 48Met Lys Leu Lys Gln
Ile Ala Ser Ala Leu Met Met Leu Gly Ile Ser1 5 10 15cct ttg gca ttt
gcc gac ttc acc atc caa gac atc cgt gtc gaa ggc 96Pro Leu Ala Phe
Ala Asp Phe Thr Ile Gln Asp Ile Arg Val Glu Gly 20 25 30ttg cag cgt
acc gag ccg agc acc gta ttc aac tac ctg ccc gtc aaa 144Leu Gln Arg
Thr Glu Pro Ser Thr Val Phe Asn Tyr Leu Pro Val Lys 35 40 45gtc ggc
gac acc tac aac gac aca cac ggc agt gcc atc atc aaa agc 192Val Gly
Asp Thr Tyr Asn Asp Thr His Gly Ser Ala Ile Ile Lys Ser 50 55 60ctg
tac gcc acc ggt ttc ttt gac gac gta cga gtc gaa act gcg gac 240Leu
Tyr Ala Thr Gly Phe Phe Asp Asp Val Arg Val Glu Thr Ala Asp65 70 75
80ggg ctg ctt ctg ctg acc gtt atc gta tgc cct acc atc ggc tcg ctc
288Gly Leu Leu Leu Leu Thr Val Ile Val Cys Pro Thr Ile Gly Ser Leu
85 90 95aac atc acc ggc gcc aaa atg ctg cag aac gac gcc atc aag aaa
aac 336Asn Ile Thr Gly Ala Lys Met Leu Gln Asn Asp Ala Ile Lys Lys
Asn 100 105 110ctc gaa tcg ttc ggg ctg gcg cag tcg caa tac ttt aat
cag gcg aca 384Leu Glu Ser Phe Gly Leu Ala Gln Ser Gln Tyr Phe Asn
Gln Ala Thr 115 120 125ctc aac cag gca gtc gcc ggc ctg aaa gaa gaa
tat ctc ggg cgc ggc 432Leu Asn Gln Ala Val Ala Gly Leu Lys Glu Glu
Tyr Leu Gly Arg Gly 130 135 140aaa ctc aat atc caa atc acg ccc aaa
gta acc aaa ctc gcc cgc aac 480Lys Leu Asn Ile Gln Ile Thr Pro Lys
Val Thr Lys Leu Ala Arg Asn145 150 155 160cgc gtc gac atc gac atc
acg att gac gag ggc aaa tcc gcc aaa atc 528Arg Val Asp Ile Asp Ile
Thr Ile Asp Glu Gly Lys Ser Ala Lys Ile 165 170 175acc gac atc gaa
ttt gaa ggc aac caa gtc tat tcc gac cgc aaa ctg 576Thr Asp Ile Glu
Phe Glu Gly Asn Gln Val Tyr Ser Asp Arg Lys Leu 180 185 190atg cgg
cag atg tcg ctg acc gaa ggc ggc att tgg aca tgg ctg aca 624Met Arg
Gln Met Ser Leu Thr Glu Gly Gly Ile Trp Thr Trp Leu Thr 195 200
205cga agc gac cgg ttc gac cgc cag aaa ttc gcc caa gac atg gaa aaa
672Arg Ser Asp Arg Phe Asp Arg Gln Lys Phe Ala Gln Asp Met Glu Lys
210 215 220gta acc gac ttc tac cag aac aac ggc tac ttc gat ttc cgt
atc ctc 720Val Thr Asp Phe Tyr Gln Asn Asn Gly Tyr Phe Asp Phe Arg
Ile Leu225 230 235 240gat acc gac atc caa acc aac gaa gac aaa acc
agg cag acc atc aaa 768Asp Thr Asp Ile Gln Thr Asn Glu Asp Lys Thr
Arg Gln Thr Ile Lys 245 250 255atc acc gtc cac gaa ggc gga cgt ttc
cgc tgg ggc aaa gtg tcg att 816Ile Thr Val His Glu Gly Gly Arg Phe
Arg Trp Gly Lys Val Ser Ile 260 265 270gaa ggc gac acc aac gaa gtc
ccc aag gcc gaa ctg gaa aaa ctg ctg 864Glu Gly Asp Thr Asn Glu Val
Pro Lys Ala Glu Leu Glu Lys Leu Leu 275 280 285acc atg aag ccc ggc
aaa tgg tac gaa cgc cag cag atg acc gcc gtt 912Thr Met Lys Pro Gly
Lys Trp Tyr Glu Arg Gln Gln Met Thr Ala Val 290 295 300ttg ggt gag
att cag aac cgc atg ggc tcg gca ggc tac gca tac agc 960Leu Gly Glu
Ile Gln Asn Arg Met Gly Ser Ala Gly Tyr Ala Tyr Ser305 310 315
320gaa atc agc gta cag ccg ctg ccg aac gcc gga acc aaa acc gtc gat
1008Glu Ile Ser Val Gln Pro Leu Pro Asn Ala Gly Thr Lys Thr Val Asp
325 330 335ttc gtc ctg cac atc gaa ccg ggc aga aaa atc tac gtc aac
gaa atc 1056Phe Val Leu His Ile Glu Pro Gly Arg Lys Ile Tyr Val Asn
Glu Ile 340 345 350cac atc acc ggc aac aac aaa acc cgc gac gaa gtc
gtg cgc cgc gaa 1104His Ile Thr Gly Asn Asn Lys Thr Arg Asp Glu Val
Val Arg Arg Glu 355 360 365ttg cgc caa atg gaa tcc gcg cct tac gac
acc tcc aag ctg caa cgc 1152Leu Arg Gln Met Glu Ser Ala Pro Tyr Asp
Thr Ser Lys Leu Gln Arg 370 375 380tcc aaa gag cgc gtc gag ctt ttg
ggc tac ttc gac aac gta cag ttt 1200Ser Lys Glu Arg Val Glu Leu Leu
Gly Tyr Phe Asp Asn Val Gln Phe385 390 395 400gat gcc gtc ccg ctt
gcc ggt acg ccc gac aaa gtc gat ttg aac atg 1248Asp Ala Val Pro Leu
Ala Gly Thr Pro Asp Lys Val Asp Leu Asn Met 405 410 415agc ctg acc
gaa cgt tcc acc ggc tcg ctc gac ttg agc gcg ggc tgg 1296Ser Leu Thr
Glu Arg Ser Thr Gly Ser Leu Asp Leu Ser Ala Gly Trp 420 425 430gtt
cag gat acc ggc ttg gtc atg tcc gcc ggc gta tcg cag gac aac 1344Val
Gln Asp Thr Gly Leu Val Met Ser Ala Gly Val Ser Gln Asp Asn 435 440
445ctg ttc ggt acg ggc aag tcg gcc gcc ctg cgc gcc tcg cga agc aaa
1392Leu Phe Gly Thr Gly Lys Ser Ala Ala Leu Arg Ala Ser Arg Ser Lys
450 455 460acc acg ctc aac ggc tcg ctg tcg ttt acc gac ccg tac ttc
acg gca 1440Thr Thr Leu Asn Gly Ser Leu Ser Phe Thr Asp Pro Tyr Phe
Thr Ala465 470 475 480gac ggg gtc agc ctg ggc tac gat att tac gga
aaa gcc ttc gac ccg 1488Asp Gly Val Ser Leu Gly Tyr Asp Ile Tyr Gly
Lys Ala Phe Asp Pro 485 490 495cgc aaa gca tcg acc agc gtc aaa caa
tat aaa acc acc acc gcc ggc 1536Arg Lys Ala Ser Thr Ser Val Lys Gln
Tyr Lys Thr Thr Thr Ala Gly 500 505 510ggc ggc gta agg atg ggt atc
ccc gtt acc gaa tac gac cgc gtc aat 1584Gly Gly Val Arg Met Gly Ile
Pro Val Thr Glu Tyr Asp Arg Val Asn 515 520 525ttc ggg ctg gcg gcg
gaa cac ctg acc gtc aac acc tac aac aaa gca 1632Phe Gly Leu Ala Ala
Glu His Leu Thr Val Asn Thr Tyr Asn Lys Ala 530 535 540ccc aaa cgc
tat gcc gac ttt atc aaa caa tac ggc aaa acc gac ggc 1680Pro Lys Arg
Tyr Ala Asp Phe Ile Lys Gln Tyr Gly Lys Thr Asp Gly545 550 555
560gca gac ggc agc ttc aaa ggc ctg ctg tac aaa ggc act gtc ggc tgg
1728Ala Asp Gly Ser Phe Lys Gly Leu Leu Tyr Lys Gly Thr Val Gly Trp
565 570 575ggg cgc aac aag acc gac agc gcc tta tgg ccg acg cgc ggc
tac ctg 1776Gly Arg Asn Lys Thr Asp Ser Ala Leu Trp Pro Thr Arg Gly
Tyr Leu 580 585 590acc ggc gta aat gcc gaa atc gcc ctg ccc ggc agc
aaa ctg caa tac 1824Thr Gly Val Asn Ala Glu Ile Ala Leu Pro Gly Ser
Lys Leu Gln Tyr 595 600 605tac tcc gcc acc cac aac caa acc tgg ttc
ttc ccc tta agc aaa acc 1872Tyr Ser Ala Thr His Asn Gln Thr Trp Phe
Phe Pro Leu Ser Lys Thr 610 615 620ttc acg ctg atg ctc ggc ggc gaa
gtc ggc att gcg ggc ggc tac ggc 1920Phe Thr Leu Met Leu Gly Gly Glu
Val Gly Ile Ala Gly Gly Tyr Gly625 630 635 640aga acc aaa gaa atc
ccc ttc ttt gaa aac ttc tac ggc ggc ggc ctg 1968Arg Thr Lys Glu Ile
Pro Phe Phe Glu Asn Phe Tyr Gly Gly Gly Leu 645 650 655ggt tcg gtg
cgc ggc tac gaa agc ggc acg ctc ggc ccg aaa gtg tat 2016Gly Ser Val
Arg Gly Tyr Glu Ser Gly Thr Leu Gly Pro Lys Val Tyr 660 665 670gac
gaa tac ggc gaa aaa atc agc tac ggc ggc aac aaa aaa gcc aac 2064Asp
Glu Tyr Gly Glu Lys Ile Ser Tyr Gly Gly Asn Lys Lys Ala Asn 675 680
685gtc tcc gcc gag ctg ctc ttc ccg atg ccc ggt gcg aaa gac gca cgc
2112Val Ser Ala Glu Leu Leu Phe Pro Met Pro Gly Ala Lys Asp Ala Arg
690 695 700acc gtc cgc ctg agc ctg ttt gcc gac gca ggc agc gtg tgg
gac ggc 2160Thr Val Arg Leu Ser Leu Phe Ala Asp Ala Gly Ser Val Trp
Asp Gly705 710 715 720aga acc tat acc gcc gcc gaa aac ggt aac aac
aaa tcg gtt tac tcg 2208Arg Thr Tyr Thr Ala Ala Glu Asn Gly Asn Asn
Lys Ser Val Tyr Ser 725 730 735gaa aac gcg cat aaa tcc acc ttt acc
aac gaa ttg cgc tat tcc gcc 2256Glu Asn Ala His Lys Ser Thr Phe Thr
Asn Glu Leu Arg Tyr Ser Ala 740 745 750ggc ggc gcg gtt acc tgg ctc
tcg cct ttg ggc ccg atg aaa ttc atc 2304Gly Gly Ala Val Thr Trp Leu
Ser Pro Leu Gly Pro Met Lys Phe Ile 755 760 765tac gcc tac ccg ctg
aag aaa aaa ccg gaa gac gaa atc caa cgc ttc 2352Tyr Ala Tyr Pro Leu
Lys Lys Lys Pro Glu Asp Glu Ile Gln Arg Phe 770 775 780caa ttc cag
ctc ggc acg acg ttc taa 2379Gln Phe Gln Leu Gly Thr Thr Phe785
7902792PRTNeisseria gonorrhoeae 2Met Lys Leu Lys Gln Ile Ala Ser
Ala Leu Met Met Leu Gly Ile Ser1 5 10 15Pro Leu Ala Phe Ala Asp Phe
Thr Ile Gln Asp Ile Arg Val Glu Gly 20 25 30Leu Gln Arg Thr Glu Pro
Ser Thr Val Phe Asn Tyr Leu Pro Val Lys 35 40 45Val Gly Asp Thr Tyr
Asn Asp Thr His Gly Ser Ala Ile Ile Lys Ser 50 55 60Leu Tyr Ala Thr
Gly Phe Phe Asp Asp Val Arg Val Glu Thr Ala Asp65 70 75 80Gly Leu
Leu Leu Leu Thr Val Ile Val Cys Pro Thr Ile Gly Ser Leu 85 90 95Asn
Ile Thr Gly Ala Lys Met Leu Gln Asn Asp Ala Ile Lys Lys Asn 100 105
110Leu Glu Ser Phe Gly Leu Ala Gln Ser Gln Tyr Phe Asn Gln Ala Thr
115 120 125Leu Asn Gln Ala Val Ala Gly Leu Lys Glu Glu Tyr Leu Gly
Arg Gly 130 135 140Lys Leu Asn Ile Gln Ile Thr Pro Lys Val Thr Lys
Leu Ala Arg Asn145 150 155 160Arg Val Asp Ile Asp Ile Thr Ile Asp
Glu Gly Lys Ser Ala Lys Ile 165 170 175Thr Asp Ile Glu Phe Glu Gly
Asn Gln Val Tyr Ser Asp Arg Lys Leu 180 185 190Met Arg Gln Met Ser
Leu Thr Glu Gly Gly Ile Trp Thr Trp Leu Thr 195 200 205Arg Ser Asp
Arg Phe Asp Arg Gln Lys Phe Ala Gln Asp Met Glu Lys 210 215 220Val
Thr Asp Phe Tyr Gln Asn Asn Gly Tyr Phe Asp Phe Arg Ile Leu225 230
235 240Asp Thr Asp Ile Gln Thr Asn Glu Asp Lys Thr Arg Gln Thr Ile
Lys 245 250 255Ile Thr Val His Glu Gly Gly Arg Phe Arg Trp Gly Lys
Val Ser Ile 260 265 270Glu Gly Asp Thr Asn Glu Val Pro Lys Ala Glu
Leu Glu Lys Leu Leu 275 280 285Thr Met Lys Pro Gly Lys Trp Tyr Glu
Arg Gln Gln Met Thr Ala Val 290 295 300Leu Gly Glu Ile Gln Asn Arg
Met Gly Ser Ala Gly Tyr Ala Tyr Ser305 310 315 320Glu Ile Ser Val
Gln Pro Leu Pro Asn Ala Gly Thr Lys Thr Val Asp 325 330 335Phe Val
Leu His Ile Glu Pro Gly Arg Lys Ile Tyr Val Asn Glu Ile 340 345
350His Ile Thr Gly Asn Asn Lys Thr Arg Asp Glu Val Val Arg Arg Glu
355 360 365Leu Arg Gln Met Glu Ser Ala Pro Tyr Asp Thr Ser Lys Leu
Gln Arg 370 375 380Ser Lys Glu Arg Val Glu Leu Leu Gly Tyr Phe Asp
Asn Val Gln Phe385 390 395 400Asp Ala Val Pro Leu Ala Gly Thr Pro
Asp Lys Val Asp Leu Asn Met 405 410 415Ser Leu Thr Glu Arg Ser Thr
Gly Ser Leu Asp Leu Ser Ala Gly Trp 420 425 430Val Gln Asp Thr Gly
Leu Val Met Ser Ala Gly Val Ser Gln Asp Asn 435 440 445Leu Phe Gly
Thr Gly Lys Ser Ala Ala Leu Arg Ala Ser Arg Ser Lys 450 455 460Thr
Thr Leu Asn Gly Ser Leu Ser Phe Thr Asp Pro Tyr Phe Thr Ala465 470
475 480Asp Gly Val Ser Leu Gly Tyr Asp Ile Tyr Gly Lys Ala Phe Asp
Pro 485 490 495Arg Lys Ala Ser Thr Ser Val Lys Gln Tyr Lys Thr Thr
Thr Ala Gly 500 505 510Gly Gly Val Arg Met Gly Ile Pro Val Thr Glu
Tyr Asp Arg Val Asn 515 520 525Phe Gly Leu Ala Ala Glu His Leu Thr
Val Asn Thr Tyr Asn Lys Ala 530 535 540Pro Lys Arg Tyr Ala Asp Phe
Ile Lys Gln Tyr Gly Lys Thr Asp Gly545 550 555 560Ala Asp Gly Ser
Phe Lys Gly Leu Leu Tyr Lys Gly Thr Val Gly Trp 565 570 575Gly Arg
Asn Lys Thr Asp Ser Ala Leu Trp Pro Thr Arg Gly Tyr Leu 580 585
590Thr Gly Val Asn Ala Glu Ile Ala Leu Pro Gly Ser Lys Leu Gln Tyr
595 600 605Tyr Ser Ala Thr His Asn Gln Thr Trp Phe Phe Pro Leu Ser
Lys Thr 610 615 620Phe Thr Leu Met Leu Gly Gly Glu Val Gly Ile Ala
Gly Gly Tyr Gly625 630 635 640Arg Thr Lys Glu Ile Pro Phe Phe Glu
Asn Phe Tyr Gly Gly Gly Leu 645 650 655Gly Ser Val Arg Gly Tyr Glu
Ser Gly Thr Leu Gly Pro Lys Val Tyr 660 665 670Asp Glu Tyr Gly Glu
Lys Ile Ser Tyr Gly Gly Asn Lys Lys Ala Asn 675 680 685Val Ser Ala
Glu Leu Leu Phe Pro Met Pro Gly Ala Lys Asp Ala Arg 690 695 700Thr
Val Arg Leu Ser Leu Phe Ala Asp Ala Gly Ser Val Trp Asp Gly705 710
715 720Arg Thr Tyr Thr Ala Ala Glu Asn Gly Asn Asn Lys Ser Val Tyr
Ser 725 730 735Glu Asn Ala His Lys Ser Thr Phe Thr Asn Glu Leu Arg
Tyr Ser Ala 740 745 750Gly Gly Ala Val Thr Trp Leu Ser Pro Leu Gly
Pro Met Lys Phe Ile 755 760 765Tyr Ala Tyr Pro Leu Lys Lys Lys Pro
Glu Asp Glu Ile Gln Arg Phe 770 775 780Gln Phe Gln Leu Gly Thr Thr
Phe785 79032394DNANeisseria meningitidisCDS(1)..(2391) 3atg aaa ctg
aaa cag att gct tcc gca ctg atg atg ttg ggc ata tcg 48Met Lys Leu
Lys Gln Ile Ala Ser Ala Leu Met Met Leu Gly Ile Ser1 5 10 15cct ttg
gca ttt gcc gac ttc acc atc caa gac atc cgt gtc gaa ggc 96Pro Leu
Ala Phe Ala Asp Phe Thr Ile Gln Asp Ile Arg Val Glu Gly 20 25 30ttg
cag cgt acc gag ccg agc acc gta ttc aac tac ctg ccc gtc aaa 144Leu
Gln Arg Thr Glu Pro Ser Thr Val Phe Asn Tyr Leu Pro Val Lys 35 40
45gtc ggc gat acc tac aac gac aca cac ggc agt gcc atc atc aaa agc
192Val Gly Asp Thr Tyr Asn Asp Thr His Gly Ser Ala Ile Ile Lys Ser
50 55 60ctg tac gcc acc ggt ttc ttt gac gac gta cgc gtc gaa act gcg
gac 240Leu Tyr Ala Thr Gly Phe Phe Asp Asp Val Arg Val Glu Thr Ala
Asp65 70 75 80ggg cag ctc ctg ctg acc gtt atc gaa cgc ccc acc atc
ggc tcg ctc 288Gly Gln Leu Leu Leu Thr Val Ile Glu Arg Pro Thr Ile
Gly Ser Leu 85 90 95aac atc acc ggc gca aaa atg ctg caa aac gac gcc
att aag aaa aac 336Asn Ile Thr Gly Ala Lys Met Leu Gln Asn Asp Ala
Ile Lys Lys Asn 100 105 110ctc gaa tcg ttc ggg ctg gcg cag tcg caa
tac ttt aat cag gcg aca 384Leu Glu Ser Phe Gly Leu Ala Gln Ser Gln
Tyr Phe Asn Gln Ala Thr 115 120 125ctc aat cag gca gtc gcc ggc ctg
aaa gaa gaa tac ctc ggg cgc ggc 432Leu Asn Gln Ala Val Ala Gly Leu
Lys Glu Glu Tyr Leu Gly Arg Gly 130 135 140aaa ctc aat atc caa atc
acg ccc aaa gta acc aaa ctc gcc cgc aac 480Lys Leu Asn Ile Gln Ile
Thr Pro Lys Val Thr Lys Leu Ala Arg Asn145 150 155 160cgc gtc gac
atc gac atc acg att gac gag ggc aaa tcc gcc aaa atc 528Arg Val Asp
Ile Asp Ile Thr Ile Asp Glu Gly Lys Ser Ala Lys Ile 165 170 175acc
gac atc gaa ttt gaa ggc aac caa gtc tat tcc gac cgc aaa ctg 576Thr
Asp Ile Glu Phe Glu Gly Asn Gln Val Tyr Ser Asp Arg Lys Leu 180 185
190atg cgg cag atg tcg ctg acc gaa ggc ggc att tgg aca tgg ctg aca
624Met Arg Gln Met Ser Leu Thr Glu Gly Gly Ile Trp Thr Trp Leu Thr
195 200 205cga agc aac caa ttc aac gag cag aaa ttt gcc caa gac atg
gaa aaa 672Arg Ser Asn Gln Phe Asn Glu Gln Lys Phe Ala Gln Asp Met
Glu Lys 210 215 220gta acc gac ttc tac cag aac aac ggc tac ttc gat
ttc cgt atc ctc 720Val Thr Asp Phe Tyr Gln Asn Asn Gly Tyr Phe Asp
Phe Arg Ile Leu225 230 235 240gat acc gac atc caa acc aac gaa gac
aaa
acc aag cag acc atc aaa 768Asp Thr Asp Ile Gln Thr Asn Glu Asp Lys
Thr Lys Gln Thr Ile Lys 245 250 255atc acc gtc cac gaa ggc gga cgt
ttc cgt tgg ggc aaa gtc tcc atc 816Ile Thr Val His Glu Gly Gly Arg
Phe Arg Trp Gly Lys Val Ser Ile 260 265 270gaa ggc gac acc aac gaa
gtc ccc aaa gcc gaa ctg gaa aaa ctg ctg 864Glu Gly Asp Thr Asn Glu
Val Pro Lys Ala Glu Leu Glu Lys Leu Leu 275 280 285acc atg aag ccc
ggc aaa tgg tac gaa cgc cag cag atg acc gcc gtt 912Thr Met Lys Pro
Gly Lys Trp Tyr Glu Arg Gln Gln Met Thr Ala Val 290 295 300ttg ggt
gag att cag aac cgc atg ggc tcg gca ggc tac gca tac agc 960Leu Gly
Glu Ile Gln Asn Arg Met Gly Ser Ala Gly Tyr Ala Tyr Ser305 310 315
320gaa atc agc gta cag ccg ctg cca aac gcc gaa acc aaa acc gtc gat
1008Glu Ile Ser Val Gln Pro Leu Pro Asn Ala Glu Thr Lys Thr Val Asp
325 330 335ttc gtc ctg cac atc gaa ccg ggc cgg aaa atc tac gtc aac
gaa atc 1056Phe Val Leu His Ile Glu Pro Gly Arg Lys Ile Tyr Val Asn
Glu Ile 340 345 350cac atc acc ggc aac aac aaa acc cgc gac gaa gtc
gtg cgc cgc gaa 1104His Ile Thr Gly Asn Asn Lys Thr Arg Asp Glu Val
Val Arg Arg Glu 355 360 365ttg cgc caa atg gaa tcc gcg cct tac gac
acc tcc aag ctg caa cgc 1152Leu Arg Gln Met Glu Ser Ala Pro Tyr Asp
Thr Ser Lys Leu Gln Arg 370 375 380tcc aaa gag cgc gtc gag ctt ttg
ggc tac ttc gac aac gta cag ttt 1200Ser Lys Glu Arg Val Glu Leu Leu
Gly Tyr Phe Asp Asn Val Gln Phe385 390 395 400gat gcc gtc ccg ctt
gcc ggc aca ccc gac aaa gtc gat ttg aac atg 1248Asp Ala Val Pro Leu
Ala Gly Thr Pro Asp Lys Val Asp Leu Asn Met 405 410 415agc ctg acc
gaa cgt tcc acc ggc tcg ctc gac ttg agc gcg ggc tgg 1296Ser Leu Thr
Glu Arg Ser Thr Gly Ser Leu Asp Leu Ser Ala Gly Trp 420 425 430gta
cag gat acc ggc ctg gtc atg tcc gca ggc gtt tcc caa gac aac 1344Val
Gln Asp Thr Gly Leu Val Met Ser Ala Gly Val Ser Gln Asp Asn 435 440
445ctg ttc ggt acg ggc aag tcg gcc gcc ctg cgc gcc tca cga agc aaa
1392Leu Phe Gly Thr Gly Lys Ser Ala Ala Leu Arg Ala Ser Arg Ser Lys
450 455 460acc acg ctc aac ggc tcg ctg tcg ttt acc gac ccg tac ttc
acg gca 1440Thr Thr Leu Asn Gly Ser Leu Ser Phe Thr Asp Pro Tyr Phe
Thr Ala465 470 475 480gac ggg gtc agc ctg ggc tac gat gtt tac gga
aaa gcc ttc gac ccg 1488Asp Gly Val Ser Leu Gly Tyr Asp Val Tyr Gly
Lys Ala Phe Asp Pro 485 490 495cgc aaa gca tcg acc agc atc aaa caa
tat aaa acc acc acg gca ggc 1536Arg Lys Ala Ser Thr Ser Ile Lys Gln
Tyr Lys Thr Thr Thr Ala Gly 500 505 510gca ggc atc cgc atg agc gtg
cct gtt acc gaa tac gac cgc gtg aat 1584Ala Gly Ile Arg Met Ser Val
Pro Val Thr Glu Tyr Asp Arg Val Asn 515 520 525ttc ggt ttg gtg gca
gaa cac ctg acc gtc aac acc tac aac aaa gcg 1632Phe Gly Leu Val Ala
Glu His Leu Thr Val Asn Thr Tyr Asn Lys Ala 530 535 540ccc aaa cac
tat gcc gac ttt atc aag aaa tac ggc aaa acc gac ggc 1680Pro Lys His
Tyr Ala Asp Phe Ile Lys Lys Tyr Gly Lys Thr Asp Gly545 550 555
560aca gac ggc agc ttc aaa ggc tgg ctg tac aaa ggt acc gtc ggc tgg
1728Thr Asp Gly Ser Phe Lys Gly Trp Leu Tyr Lys Gly Thr Val Gly Trp
565 570 575ggg cgc aac aaa acc gac agc gcg tta tgg ccg acg cgc ggc
tac ctg 1776Gly Arg Asn Lys Thr Asp Ser Ala Leu Trp Pro Thr Arg Gly
Tyr Leu 580 585 590acg ggc gtg aac gcc gaa atc gcc ctg ccc ggc agc
aaa ctg caa tac 1824Thr Gly Val Asn Ala Glu Ile Ala Leu Pro Gly Ser
Lys Leu Gln Tyr 595 600 605tac tcc gcc acc cac aac caa acc tgg ttc
ttc ccc tta agc aaa acc 1872Tyr Ser Ala Thr His Asn Gln Thr Trp Phe
Phe Pro Leu Ser Lys Thr 610 615 620ttc acg ctg atg ctc ggc ggc gaa
gtc ggc att gcg ggc ggc tac ggc 1920Phe Thr Leu Met Leu Gly Gly Glu
Val Gly Ile Ala Gly Gly Tyr Gly625 630 635 640aga acc aaa gaa atc
ccc ttc ttt gaa aac ttc tac ggc ggc ggc ctg 1968Arg Thr Lys Glu Ile
Pro Phe Phe Glu Asn Phe Tyr Gly Gly Gly Leu 645 650 655ggt tcg gtg
cgc gga tac gaa agc ggc acg ctc ggt ccg aaa gtg tat 2016Gly Ser Val
Arg Gly Tyr Glu Ser Gly Thr Leu Gly Pro Lys Val Tyr 660 665 670gac
gaa tac ggc gaa aaa atc agc tac ggc ggc aac aaa aaa gcc aac 2064Asp
Glu Tyr Gly Glu Lys Ile Ser Tyr Gly Gly Asn Lys Lys Ala Asn 675 680
685gtc tcc gcc gag ctg ctc ttc ccg atg cct ggc gcg aaa gac gcg cgc
2112Val Ser Ala Glu Leu Leu Phe Pro Met Pro Gly Ala Lys Asp Ala Arg
690 695 700acc gtc cgc ctg agc ctg ttt gcc gac gca ggc agc gtg tgg
gac ggc 2160Thr Val Arg Leu Ser Leu Phe Ala Asp Ala Gly Ser Val Trp
Asp Gly705 710 715 720aaa acc tac gac gac aac agc agt tcc gcg acc
ggc ggc agg gtt caa 2208Lys Thr Tyr Asp Asp Asn Ser Ser Ser Ala Thr
Gly Gly Arg Val Gln 725 730 735aac att tac ggc gcc ggc aat acc cat
aaa tcc acc ttt acc aac gaa 2256Asn Ile Tyr Gly Ala Gly Asn Thr His
Lys Ser Thr Phe Thr Asn Glu 740 745 750ttg cgc tat tcc gcc ggc ggc
gcg gtt acc tgg ctc tcg cct tta ggc 2304Leu Arg Tyr Ser Ala Gly Gly
Ala Val Thr Trp Leu Ser Pro Leu Gly 755 760 765ccg atg aaa ttc agg
tac gcc tac ccg ctg aag aaa aaa ccg gaa gac 2352Pro Met Lys Phe Arg
Tyr Ala Tyr Pro Leu Lys Lys Lys Pro Glu Asp 770 775 780gaa atc caa
cgc ttc caa ttc caa ctc ggc acg acg ttc taa 2394Glu Ile Gln Arg Phe
Gln Phe Gln Leu Gly Thr Thr Phe785 790 7954797PRTNeisseria
meningitidis 4Met Lys Leu Lys Gln Ile Ala Ser Ala Leu Met Met Leu
Gly Ile Ser1 5 10 15Pro Leu Ala Phe Ala Asp Phe Thr Ile Gln Asp Ile
Arg Val Glu Gly 20 25 30Leu Gln Arg Thr Glu Pro Ser Thr Val Phe Asn
Tyr Leu Pro Val Lys 35 40 45Val Gly Asp Thr Tyr Asn Asp Thr His Gly
Ser Ala Ile Ile Lys Ser 50 55 60Leu Tyr Ala Thr Gly Phe Phe Asp Asp
Val Arg Val Glu Thr Ala Asp65 70 75 80Gly Gln Leu Leu Leu Thr Val
Ile Glu Arg Pro Thr Ile Gly Ser Leu 85 90 95Asn Ile Thr Gly Ala Lys
Met Leu Gln Asn Asp Ala Ile Lys Lys Asn 100 105 110Leu Glu Ser Phe
Gly Leu Ala Gln Ser Gln Tyr Phe Asn Gln Ala Thr 115 120 125Leu Asn
Gln Ala Val Ala Gly Leu Lys Glu Glu Tyr Leu Gly Arg Gly 130 135
140Lys Leu Asn Ile Gln Ile Thr Pro Lys Val Thr Lys Leu Ala Arg
Asn145 150 155 160Arg Val Asp Ile Asp Ile Thr Ile Asp Glu Gly Lys
Ser Ala Lys Ile 165 170 175Thr Asp Ile Glu Phe Glu Gly Asn Gln Val
Tyr Ser Asp Arg Lys Leu 180 185 190Met Arg Gln Met Ser Leu Thr Glu
Gly Gly Ile Trp Thr Trp Leu Thr 195 200 205Arg Ser Asn Gln Phe Asn
Glu Gln Lys Phe Ala Gln Asp Met Glu Lys 210 215 220Val Thr Asp Phe
Tyr Gln Asn Asn Gly Tyr Phe Asp Phe Arg Ile Leu225 230 235 240Asp
Thr Asp Ile Gln Thr Asn Glu Asp Lys Thr Lys Gln Thr Ile Lys 245 250
255Ile Thr Val His Glu Gly Gly Arg Phe Arg Trp Gly Lys Val Ser Ile
260 265 270Glu Gly Asp Thr Asn Glu Val Pro Lys Ala Glu Leu Glu Lys
Leu Leu 275 280 285Thr Met Lys Pro Gly Lys Trp Tyr Glu Arg Gln Gln
Met Thr Ala Val 290 295 300Leu Gly Glu Ile Gln Asn Arg Met Gly Ser
Ala Gly Tyr Ala Tyr Ser305 310 315 320Glu Ile Ser Val Gln Pro Leu
Pro Asn Ala Glu Thr Lys Thr Val Asp 325 330 335Phe Val Leu His Ile
Glu Pro Gly Arg Lys Ile Tyr Val Asn Glu Ile 340 345 350His Ile Thr
Gly Asn Asn Lys Thr Arg Asp Glu Val Val Arg Arg Glu 355 360 365Leu
Arg Gln Met Glu Ser Ala Pro Tyr Asp Thr Ser Lys Leu Gln Arg 370 375
380Ser Lys Glu Arg Val Glu Leu Leu Gly Tyr Phe Asp Asn Val Gln
Phe385 390 395 400Asp Ala Val Pro Leu Ala Gly Thr Pro Asp Lys Val
Asp Leu Asn Met 405 410 415Ser Leu Thr Glu Arg Ser Thr Gly Ser Leu
Asp Leu Ser Ala Gly Trp 420 425 430Val Gln Asp Thr Gly Leu Val Met
Ser Ala Gly Val Ser Gln Asp Asn 435 440 445Leu Phe Gly Thr Gly Lys
Ser Ala Ala Leu Arg Ala Ser Arg Ser Lys 450 455 460Thr Thr Leu Asn
Gly Ser Leu Ser Phe Thr Asp Pro Tyr Phe Thr Ala465 470 475 480Asp
Gly Val Ser Leu Gly Tyr Asp Val Tyr Gly Lys Ala Phe Asp Pro 485 490
495Arg Lys Ala Ser Thr Ser Ile Lys Gln Tyr Lys Thr Thr Thr Ala Gly
500 505 510Ala Gly Ile Arg Met Ser Val Pro Val Thr Glu Tyr Asp Arg
Val Asn 515 520 525Phe Gly Leu Val Ala Glu His Leu Thr Val Asn Thr
Tyr Asn Lys Ala 530 535 540Pro Lys His Tyr Ala Asp Phe Ile Lys Lys
Tyr Gly Lys Thr Asp Gly545 550 555 560Thr Asp Gly Ser Phe Lys Gly
Trp Leu Tyr Lys Gly Thr Val Gly Trp 565 570 575Gly Arg Asn Lys Thr
Asp Ser Ala Leu Trp Pro Thr Arg Gly Tyr Leu 580 585 590Thr Gly Val
Asn Ala Glu Ile Ala Leu Pro Gly Ser Lys Leu Gln Tyr 595 600 605Tyr
Ser Ala Thr His Asn Gln Thr Trp Phe Phe Pro Leu Ser Lys Thr 610 615
620Phe Thr Leu Met Leu Gly Gly Glu Val Gly Ile Ala Gly Gly Tyr
Gly625 630 635 640Arg Thr Lys Glu Ile Pro Phe Phe Glu Asn Phe Tyr
Gly Gly Gly Leu 645 650 655Gly Ser Val Arg Gly Tyr Glu Ser Gly Thr
Leu Gly Pro Lys Val Tyr 660 665 670Asp Glu Tyr Gly Glu Lys Ile Ser
Tyr Gly Gly Asn Lys Lys Ala Asn 675 680 685Val Ser Ala Glu Leu Leu
Phe Pro Met Pro Gly Ala Lys Asp Ala Arg 690 695 700Thr Val Arg Leu
Ser Leu Phe Ala Asp Ala Gly Ser Val Trp Asp Gly705 710 715 720Lys
Thr Tyr Asp Asp Asn Ser Ser Ser Ala Thr Gly Gly Arg Val Gln 725 730
735Asn Ile Tyr Gly Ala Gly Asn Thr His Lys Ser Thr Phe Thr Asn Glu
740 745 750Leu Arg Tyr Ser Ala Gly Gly Ala Val Thr Trp Leu Ser Pro
Leu Gly 755 760 765Pro Met Lys Phe Arg Tyr Ala Tyr Pro Leu Lys Lys
Lys Pro Glu Asp 770 775 780Glu Ile Gln Arg Phe Gln Phe Gln Leu Gly
Thr Thr Phe785 790 795523DNAArtificial SequencePCR primer
5cggaattcat gaaactgaaa cag 23618DNAArtificial SequencePCR primer
6ttgcagtttt tgcaattc 18759DNANeisseria gonorrhoeae 7tagattttac
gtttcggaat gcagtctgaa accgcattcc gcaccacaag gaacttacg
59867DNANeisseria gonorrhoeae 8cccgcaaatg ccgtctgaag cccttgagac
ggcatttcgc ggcaacatcc gaaggagttt 60taccatg 67
* * * * *